Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
4 - Continuous or	Randomis	1+	203 patients	Patients with	Oxygen	Mortality,		Pulmonary	Mortality in the	NIH
nocturnal oxygen	ed			hypoxemic	therapy or	pulmonary		haemodynami	nocuturnal	
therapy in hypoxemic	controlled			chronic	12 hours	haemodynam	,	c mortality	oxygen therapy	
chronic obstructive	trial			obstructive	nocturnal	ics, exercise	months)		group was 1.94	
lung disease: a clinical				pulmonary	oxygen	capacity			times that of	
trial. Nocturnal Oxygen				disease.Stable	therapy				continuous	
Therapy Trial Group.				hypoxemic					oxygen therapy	
Annals of Internal				patients with					group (p=0.01).	
Medicine 1980,				COPD PaO2					This trend was	
93(3):391-8				55mmHg or					more apparent	
				less , or Pao2					in patients with	
				59mmHg or					carbon dioxide	
				less with signs					retention and	
				of right heart					also in patients	
				failure (					with relatively	
				oedema or p					poor lung	
				pulmonale 0					function at low	
				or					nocturnal	
				erythrocytosis					oxygen	
				(hct greater					saturation,	
				than or equal					more severe	
				to 55). FEV1					brain	
				30% pred,					dysfunction and	
				PaO2 51					prominent	
				mmHg , PaCO2					disturbances.	
				43 mmHg					The benefits to	
									patients with	
	1	1								

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
5 - Long term	Randomis	1+	33 males, 9	Men and	Oxygen	Mortality,	2000 days	Survival,	19 of 42 oxygen	MRC
domiciliary oxygen	ed		females	women under	therapy	hospital		hospital	treated patients	
therapy in chronic	controlled		treated with	70 years of age	release 15	admissions		admissions,	died in 5 year	
hypoxic cor pulmonale	trial		longterm	with chronic	hours per	with		red cell mass,	survival follow	
complicating chronic			oxygen	bronchitis and	day by nasal	exacerbations		pulmonary	up compared	
bronchitis and			therapy, 33	emphysema,	prong. Flow	, red cell mass		arterial	with 30 of 45	
emphysema. Report of			male, 12	irreversible	rate?to a	pulmonary		pressure in	control. In 66	
the Medical Research			female	airways	minute or	arterial		this subgroup	men survival	
Council Working Party.			controls	obstruction	higher flow	pressure in			advantage did	
Lancet			FEV1 0.75,	FEV1<1.2 ltr	rate to	this subgroup			not emerge	
1981;317(8222):681-6			PaO2 51	and PaO2 40-	achieve PO2				until 500 days	
			mmHg ,	60 mm Hg	>16 mm Hg.				had elapsed.	
			PaO2 55	breathing air	Treatment				Survival for the	
			mmHg	at rest with	over 2,000				12 female	
				history of	days				controls was	
				admission with					poor. A	
				recorded					summation of	
				episode of					arterial carbon	
				heart failure					dioxide? and	
				with ankle					red cell mass	
				oedema					was helpful for	
				studied in					predicted	
				stable state					survival. Neither	
				with arterial					time spent at	
				blood gas FEV1					hospital	
				and body					because of	
				weight					exacerbations	

1/12/2014

2

Bibliographic citation	Study type	level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
6 Cooper C.B, Waterhouse J, Howard, P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 1987;42:105-110.	Cohort	2-	72 (uncontrolle d)	COPD patients with hypoxic cor pulmonale (Pa)2 <60mmHg, of which 57 had PaCO2 >6kPa). Exclusion criteria "unlikely to comply"	LTOT ≥ 15 hours/day	Compared to MRC study's normal/untre ated male (rather than control in own study)		haemodynami cs (in 45/72) including PAP, CO and pulmoanry vascualr	Significant survival benefit of LTOT immediately on starting treatment. 10 yr survival 26%. No difference in survival if PAP >25 mmHg. 5 yr survival without treatment <42%) comapred to 62% survival	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
7 Strom K. Survival of	Cohort	2-	403 (201	From Swedish	LTOT.	Subgroup	2 yrs (at 6/12	Survival (and	Significantly	Swedish heart-
patients with chronic	study		male)	data register	Ensured	analysis	intervals)	sex-related	better survival	lung
obstructive pulmonary				for LTOT	medically	within		differences),	in femals than	foundation
disease receiving long-				prescribed for	optimised	register		spirometry	males if not	
term domiciliary				chronic	and hypoxia	patients		and WHO	receiving	
oxygen therapy. Am				hypoxaemia	was stable	(looking at		status	steroid	
Rev Respir Dis				secondary to	with oxygen	COPd/asthma			maintenance.	
1993;147(3):585-591.				COPD	for Pa)2	/alfa-1			FEV1 best	
					>60mmHg)	antitrypsin			predictor of	
					over 3/52	deficiency)			long-term	
					period				survival in LTOT	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
8 - Gulbas G, Gunen H,	Cohort	2-	228 patients	COPD patients	Oxygen	Patients	Mean	Effects of ?	nil	
In E, Kilic T. Long-term	study			hypoxemia,	therapy 15	grouped into	duration of	survival are		
follow-up of chronic					h/day, SCO2	non-utilisers,	follow up	similar		
obstructive pulmonary				Hg or SCO2≤88		intermittent	27.8±18.5	between		
disease patients on				%; PaO2 56-59		utilisers (<15	months	groups		
long-term oxygen				mm Hg or		h/day) and		(19.5±5.6,		
treatment.				SCO2 at 89%		true utilisers		32.5±4.1 and		
International Journal of				at one of the		(15 h/day or		30.0±5.7		
Clinical Practice				following?		longer)		months		
2012;66(2):152-7				>55,				respectively,		
, , ,				congestive				p>0.05).		
				heart failure or				Compared		
				pulmonary				with group 1		
				hypertension				survival was		
				''				poor in group		
								2 (p<0.05).		
								There was a		
								positive trend		
								for group 3		
								during the first		
								3 yr period.		
								However this		
								improvement		
								disappears		
								during further		
								follow up.		
								Analysis of		

1/12/2014

5

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
10- Machado ML,	Cohort	2-	435 patients	COPD patients	Longterm	Mortality,	7 yrs of only	Mortality	After	ATS
Krishnan JA, Buist SA,	study		with COPD -	enrolled in	oxygen	difference	15% of the	,	accounting for	
Bilderback AL, Fazolo	,		184 women	longterm	therapy 15	between	initial studied		potential	
GP, Santarosa MG,			251 men.	oxygen	hr/day	groups	cohort had a		confounders of	
Queiroga F Jr, Vollmer			COPD	treatment			follow up		age, pack years	
WM. Sex differences in			patients	programme.			time >48		smoked, PaO2,	
survival of oxygen-			referred for	Patients			months		FEV1, BMI	
dependent patients			longterm	prescribed					females were at	
with chronic			oxygen	longterm					significantly	
obstructive pulmonary			therapy to	oxygen					higher risk of	
disease. American			respiratory	therapy					death (hazard	
Journal of Respiratory			clinics in	according to					ratio 1.54, 95%	
& Critical Care			Brazil.	GOLD/BTS					CI 1.15-2.07,	
Medicine				guidelines,					p=0.004). Other	
2006;174(5):524-9				FEV1 pred					independent	
				31.4±8% PaO2					predictors of	
				51.7±5.5 mm					death were	
				Hg. Similar					lower PaO2	
				characteristics					(p<0.001) and	
				for males and					lower BMI	
				females except					(p<0.05).	
				that female						
				younger, less						
				pack years						
				smoking						
				history.						

1/12/2014

6

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
11 Zielinski J, MacNee	Retrospec	3	215 (161	COPD patients	All deaths of	Nil	30/12 period	Cause of death	Majority had	Unknown
W, Wedzicha J, et al.	tive		males, 54	on LTOT with	LTOT				slow	
Causes of death in	questionn		females)	FEV1/FVC<55	patients at				progressive	
patients with COPD and	aire (on			% and PaO2 <8	specific				clinical course	
chronic respiratory	cohort)			on air	centres				before death.	
failure. Monaldi Arch									Lower PaCO2	
Ches Dis 1997; 52:43-									and less oxygen	
47.									useage	
									associated with	
									sudden,	
									unexpected	
									death from	
									arrythmia (not	
									statistically	
									sinificant)	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
12 - Chailleux E,	Cohort	2-	26140	Chronic	Longterm	Longterm	9 yrs	Survival	Mean survival	unknown
Laaban J-P, Veale D.	study		patients	bronchitis	oxygen	oxygen	,		for patients	
Prognostic value of			receiving	12043; asthma		therapy or			with chronic	
nutritional depletion in			LTOT or	1755; <sup>′</sup>	prolonged	prolonged			bronchitis 3 yrs,	
patients with COPD				bronchiectasis	mechanical	mechanical			survival is	
treated by long-term			mechanical	1556;	ventilation	ventilation			slightly better	
oxygen therapy: data			ventilation	emphysema					for patients	
from the ANTADIR			(noninvasive						with	
observatory. Chest			?	tuberculosis					bronchiectasis	
2003;123(5):1460-6			tracheostom	sequellae					and asthma and	
			y) 1 Jan 1984	4147;					worse for those	
			and 1 Jan	kyphoscoliosis					with	
			1993.	1574;					emphysema.	
				neuromuscular					Patients with	
				disease 1097;					kyphoscoliosis,	
				pneumoconios					neuromuscular	
				is 919; fibrosis					disease have	
				2498					longer survival	
									(8 and 6.5 yrs	
									respectively).	
									Patients with	
									chronic	
									respiratory due	
									to tuberculosis	
									sequellae	
									experience the	
									same survival as	

-	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
13 Fleetham JA, Bradley	Randomis	1+	30 patients	Hypoxemic	24 hr	Ventilatory	6 months in	Ventilatory	? hypoxia	?
CA, Kryger MH,	ed		with	patients with	continuous	and p 0.1	30 patients,	and p 0.1	responses	
Anthonisen NR. The	controlled		hypoxemic	COPD	oxygen or 12	responses to	1 year in 13	responses to	showed no	
effect of low flow	trial		chronic		hr nocturnal	CO2 and	patients	CO2 and	increase after	
oxygen therapy on the			obstructive		oxygen	hypoxia		hypoxia	either	
chemical control of			pulmonary		therapy				continuous or	
ventilation in patients			disease						nocturnal	
with hypoxemic COPD.									oxygen therapy	
The American Review									but were	
of Respiratory Disease									further reduced	
1980;122(6):833-40									after 6 months	
									of 12 hours	
									nocturnal	
									oxygen. The	
									responses to	
									CO2 were	
									depressed after	
									6 months of 24	
									hour oxygen	
									therapy and	
									were associated	
									with a	
									significant	
									increase in	
									PCO2. Change	
									in PCO2 after	
									nocturnal	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
14- Timms, R. M.;	Non-	1+	203 patients		Continuous	Pulmonary	6 months	Pulmonary	Neither oxygen	NIH
Khaja, F. U.; Williams,	randomis			hypoxemic		haemodynam		vascular	therapy	
G. W. Hemodynamic	ed			patients with	oxygen	ics		resistance,	resulted in	
response to oxygen	controlled			COPD PaO2	therapy			pulmonary	correction or	
therapy in chronic	trial			55mmHg or	',			arterial	near correction	
obstructive pulmonary				less , or Pao2				pressure/volu	of baseline	
disease. Annals of				59mmHgor				me index at	haemodynamic	
Internal Medicine				less with signs				rest and at	abnormalities.	
1985;102(1): 29-36				of right heart				exercise	Continuous	
, ( ,				failure or					oxygen therapy	
				erythrocytosis					group showed	
				′ ′					an	
									improvement in	
									pulmonary	
									vascular	
									resistance,	
									pulmonary	
									arterial	
									pressure and	
									stroke volume	
									index.	
									Improvement in	
									pulmonary	
									vascular	
									resistance is	
									associated with	
									an improved	

type level characteristic s  15 W. MacNee, A.D. Morgan Right Ventricular Performance during Exercise in COPD. Respiration 48 206-215    The performance during   COPD patients   SECOPD   SECOPD	ographic citation	Funding
S Observation al obse	•	
15 W. MacNee, A.D. Morgan Right Ventricular Performance during Exercise in COPD. Respiration 48 206-215    Absolute of the acute of the		
hours a day	an Right Ventricular rmance during ise in COPD.	(+/- r 6 /gen

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
				S						
• •	Case	2-	-	Age 47-82 yrs	no	Comparison		SGRQ quality	No statistical	Nil
EA, Jones PW,	series		controls (did		intervention	of SGRQ over		of life score	difference in	
Wedzicha JA. Does	(with			from OPD with		time and with			SGRQ scores	
ong-term oxygen	COPD			COPd	and HAD	COPD			over time on	
therapy affect quality	controls)-		LTOT) and 23	_	measured in	patients not			LTOT (but	
of life in patients with	evidence		patients on	FEV1	patients	on LTOT			patients on	
chronic obstructive	sheet as		LTOT	<1.5 L,PaO2	before LTOT				LTOT had worse	
pulmonary disease and	for cohort		(8m/15f)	<7.3 kPa, or a	and then				scores than	
severe hypoxaemia?				PaO2	after LTOT				those not/with	
ERJ 1996;9:2335-2339.				<8.0 kPa with	had been				less severe	
				evidence of	introduced				hypoxaemia)	
				cor pulmonale	at 2weeks, 3					
				(oedema and	and 6					
				ecg changes of	months.					
				right	Compared					
				ventricular	with SGRQ					
				hypertrophy).	and HAD in					
				Free from	control					
				acute	group at					
				exacerbations	same time					
				for at least 3	intervals					
				weeks before						
				entry into the						
				study. Blood						
				gas values and						
				spirometry						
				were assessed						
							l			

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
18 Heaton RK, Grant I,	RCT	1++	150 (72	COPD patients	Kept	Before/after	6/12 and	Survival,	Small sign of	Division of lung
McSweeny AJ, Adams			NOTT, 78	with	randomisati	6/12 of	12/12 post	neuropsycholo	imporvement in	disease NIH,
KM, Petty TL.			COT, 55	hypoxaemia	on from	NOT/COT	NOTT trial	gical deficit,	brain	National heart,
Psychologic effects of			COPD	and no	NOTT trial of	measured	enrollment	mood, quality	functioning with	lung and Blood
continuous and			controls, 53	exacerbations	NOT (12	neuropsych		of life	COT/NOT at	institutes
nocturnal oxygen			healthy	3/52 PaO2	hours)versus	and Quality of			6/12. At 12/12	
therapy in hypoxemic			controls)	<60mmHg on	COT (20	life			COT had greater	
chronic obstructive				air and never	hours)				significant	
pulmonary disease.				had LTOT					improvement	
Arch Int Med									than	
1983;143:1941-1947.									NOT/controls	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
19 Borak J;Sliwinski	Cohort	2+	124 eligible	COPD patients	LTOT	Before/after	12 months	Cognitive	Significant	Polish state
P;Tobiasz M;Gorecka	study		(90 survived	meeting		12 months		function,	improvement in	Reaearch
D;Zielinski J.			follow up	criteria for				psychometric	anxiety and	committee
Psychological status of			period)	LTOT (using				studies and	mood after	grant
COPD patients before				average of				attitudes	12/12 of LTOT.	
and after one year of				14.9 hours per					Significant	
long-term oxygen				day)					improvement in	
therapy. Monaldi									verbal memory	
archives for chest									and speed of	
disease 1996;51:7-11.									work (no	
									change in	
									visual/spatial	
									memory). Less	
									anxiety	
									generally in	
									hypercapnic	
									patients and	
									FEV1 correlated	
									with	
									visual/spatial	
									memory before	
									and after LTOT	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
20 Garcia-Aymerich J, Monsó E, Marrades RM, Escarrabill J, Félez MA, Sunyer J, Antó JM; EFRAM Investigators. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study. Am J Respir Crit Care Med 2001;164(6):1002- 1007.	_		86 patients		Observation	Case comapred to control group	1 year	measures  Spirometry, ABG measures, number of admissions, LTOT use and prescription, smoking habits and quality of life	Statistically significant increase in admissions (more than 3) related to lower	Generalitat de Catalunya Agencia d'Avalvacio
				died or had previously positive bronchodilator y test						

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	_	characteristic		-		measures		
				s						
21 Ringbaek TJ, Viskum	Case	3	246 COPD	Patients	Continuous	Comparison	10 months	Admission	Overall	nil
K, Lange P. Does long-	series		patients	divided into 4	(.15hrs/day	of days spent		rates were	admission rates,	
term oxygen therapy	(complete			groups. 125	or	in hospital;		days spent in	hospital days	
reduce hospitalisation	d			patients	noncontinuo	number of		hospital and	and never	
n hypoxaemic chronic	evidence			continuous	us	patients with		number of	hospitalised	
obstructive pulmonary	sheet as			oxygen	(<15hrs/day)	at least 1		patients with	were reduced	
disease? ERJ	for a			therapy (COT	LTOT	hospitalisatio		at least 1	by 23.8%,	
2002;20:38-42.	cohort)			<15 hrs /day),		n (never		hospitalisation	43.5%, and	
				who started		hospitalised)		(never	31.2%	
				LTOT at		compared in		hospitalised)	respectively.	
				hospitalisation		2 periods of			COT = 15-24 hrs	
				, 37 patients		10 months			per day oxygen;	
				on COT who		before and			nCOT =>15hrs	
				started LTOT		after			per day. Most	
				as outpatients,		inititationof			of the 162 CO2	
				58 patients on		LTOT.			patients (77.2%)	
				non-					started oxygen	
				continuous					therapy	
				oxygen					immediately	
				therapy					after	
				(nCOT) who					hospitalisation.	
			In comparison							
	at to the pre-	•								
			oxygen period							
					hospitalisation					
				patients on					days spent in	
				·						

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
hypoxaemic chronic obstructive pulmonary disease: effects of long-	and after/inte rrupted time	3	12	% pred 28.5±17.9, PaO2 7.29±1.07 kpa	Longterm oxygen therapy	Renal function before and after longterm oxygen therapy		assessed by clearances of intravenously adminstrered inulian and para-iamino-	LTOT treatment in 12 patients did not produce any significant changes in renal function for the entire study group	nil

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
23 Chambellan A, Chailleux E, Similowski T. Prognostic Value of the Hematocrit in Patients With Severe COPD Receiving Long- term Oxygen Therapy. Chest 2005;128:1201- 1208.	Cohort	2+	2524 (from total 11366 ANTADIR pts with COPD on LTOT). Of this 1799 f/u > 1yr	Hypoxaemic COPD patients between 1980- 1999	LTOT	Subgroup analyses of haematocrit ranges	mean	Haematocrit, spirometry, survival and hospital admissions (and duration of admission) all measured	Median survival on LTOT 3 yrs. Increased survival with increased haematocrit. 3 yr survival 24% if HCT <35% and 70% if HCt >55%. Equally fewer and shorter hospital admissions if HCT > 55% compared to <35%.	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
24 - Elphick H, Mallory	Systemati	2++	9 published	Patients with	Longterm	1 study	36 months	Mortality,	LTOT had no	Cochrane
GB, Fullmer JJ, Vaughan	c review		studies (149	moderate/sev	oxygen	assessed the		measure of	discernible	Collaboration
DJ. Oxygen therapy for			participants)	ere obstructive		effects of		pulmonary	effect on	
cystic fibrosis.			of which	lung disease		longterm		function and	mortality, lung	
Cochrane Database of			only 1	and cystic	supplementa	oxygen		anthropometri	function, blood	
Systematic Reviews			examined	fibrosis. Only 1	l. Four	therapy in		С	gases,	
2005;4:CD003884			longterm	study	studies	hypoxemic CF		measurements	measurements	
			oxygen	examined the	examined	participants.		, exercise test,	of nutrition,	
			therapy (28	effect of	the effects	28 children		and	mood or	
			participants)	longterm	of	and adults		radionucleotid	cognitive	
				oxygen	supplementa	were enrolled		e angiography		
				therapy in	l oxygen	in 3 Canadian		to assess right		
				patients with	during sleep	centres.		heart function,		
				CF with an FEF	by	Participants		cognitive		
				25-75>25%	polysomnogr	were		function,		
				predicted or	aphy; of	randomised		memory		
				arterialised	these studies	to receive		capacity and		
				capilliary	oxygen	oxygen		participant self	f	
				blood gas	implementat	supplementat		esteem.		
				measurement	ion	ion to achieve				
				with a	evaluated	a PaO2 of 70				
				PaO2<65 mm	during	mm Hg or				
				Hg (8.767 kpa)	exercise	room air				
				on 2 occasions		administered				
				1 week apart		from a				
						concentrator.				
						Treatment				
		<u> </u>								

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
26 Calverley PM, Leggett RJ, McElderry L, Flenley DC.Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am Rev Respir Dis. 1982 May;125(5):507- 10.		2++	47 total (15 on LTOT of which 7 smoked)	Hypoxic cor pulmonale secondary to bronchitis or emphysema (asterial hypoxaemia mean PaO2 52.5mmHg) FEV1 0.6 +/- 0.2L. Included both nonsmokers and smokers (verified by CO)	LTOT per day	Smokers v non-smokers. Comparing level of hypoxaemia and polycythaemi a	(36 month enrolment period)	Correction of arterial hypoxaemia. Red cell mass and volume	After 12/12 LTOT no change in polycythaemia (red cell mass) in the patients who still smoked. Those who stopped smoking had significant reduction in red cell mass and pulmonary artery pressures	Unknown
JR et al 1993 Value Of	Observati onal - before & after	3	113	Stable OPD COPD	Pulse Ox & ABG if SpO2<92%	SpO2 to PaO2		Sensitivity and specificity of various levels of Sao2 in the detection of hypoxaemia below 8.0 kPa and below 7.3 kPa		Undeclared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
29 Roberts, C. M. et al 1998 Screening patients in general practice with COPD for long-term domiciliary oxygen requirement using pulse oximetry Respiratory	Case controlled	2+	114	Stable COPD in primary care	Use of pulse oximetry to screen for LTOT	ABG vrs SpO2		No pts who met criteria for LTOT	3/11 pts(27%) with SpO2<92%	Undeclared
Ries AL. The use of	Observatio nal cross- sectional study	3	55	Stable patients with chronic lung disease with a resting PaO2 <8.65kPa.		PaO2 vs SpO2		Number of patients eligible for LTOT using ABG criteria vs SpO2 criteria of <85% and <88%	Using SpO2<85% would have led to underprescribing in 80%. Using SpO2<88% would have led to underand overprescribing.	Nil declared
31 Guyatt, G. H.; Nonoyama, M.; Lacchetti, C.; Goeree, R.; McKim, D.; Heels- Ansdell, D.; Goldstein, R. 2005 A randomized trial of strategies for assessing eligibility for long-term domiciliary oxygen therapy. American Journal of Respiratory and Critical Care Medicine. 172(5), 573-80	Cluster randomise d trial	1+	546	All patients (excluding palliative) referred to O2 assessment centre	Prescription of LTOT on first visit vs at 2 months to allow for clinical stability	Numbers prescribed LTOT, costs, HRQL, mortality	Í	numbers prescribed LTOT, HRQL, costs, mortality	36% less prescribed LTOT at 2 month, 15% at 1 year	Authors declare no conflict of interest with commercial copanies

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
				S						
33. Chaney JC, Jones K,	Non-	2-	283	oxygen therapy	Full review	None	Nil	demographics,	50% of those	Nil reported
Grathwohl K, Olivier	comparativ			clinic patients:				oximetry	started during	
KN.Chest. 2002; 122:1661-	e study			97 new in-				(exercise and	hospital	
1667. Implementation of				patient				overnight as	admission no	
an oxygen therapy clinic to				prescriptions; 95				able / required)	longer required	
manage users of long-				follow-ups; 91				and ABG's as	LTOT. 31.6% of	
term oxygen therapy.				new out-patient				indicated	follow-up patients	
				referrals					no-longer met	
									criteria, 56.7% of	
									new referrals	
									required LTOT.	

34 Oba Y et al Reevaluation of contnuous oxygen therpay after initial prescription in patients with COPD 2000 Respiratory Care 45(4)  Observatio nal before- after  3 TOOPD followed up after initiation of LTOT (n=19)  57 COPD followed up after initiation of LTOT (n=19)  58% of patients no longer required LTOT  FaO2 compared to guideline criteria for LTOT	Bibliographic citation	Study type	Evidence level	No patients	characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
	34 Oba Y et al Reevaluation of contnuous oxygen therpay afetr initial prescription in patients with COPD 2000 Respiratory Care 45(4) 401-6	nal before-	3	57	up after initiation	1-3 months	compared to guideline criteria for	up	number of patients eligible	no longer required	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
35 Eaton, T.; Rudkin, S.; Garrett, J. E 2001 The clinical utility of arterialized earlobe capillary blood in the assessment of patients for long-term oxygen therapy Respiratory Medicine 95 (8) 655-60	Observati onal	3	160	Referrals for LTOT assessment - mixed disease group		Those who met criteria for LTOT and those who did not		Standard measures for LTOT PaO2<7.3kPa or 8kPa if added problems	47.5% of all acute inpatient referrals required LTOT at 2 months. 30% of those given O2 at discharge did not meet criteria for LTOT at 2 months (include drop outs/deaths on intention to treat 25%)	Undeclared
36 Levi-Valensi P, Weitzenblum E, Pedinielli J-L, Racineux J-L, Duwods H. Three month follow up of arterial blood gas determinations in candidates for Long term oxygen therapy	Observatio nal before- after	3	77	COPD, ex smokers, with PaO2 between 41 and 59mmHg after 1 month clinical stability. None on LTOT	Observation for 3 months	Change in PaO2 at three months		PaO2 and number of patients eligible for LTOT	30% of patients no longer required LTOT after 3 months observation	Nil declared

Bibliographic citation	Study type	Evidence level		Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
38 Munoz X, Torres F, Sampoi G, Rios J, Marti S, Escrich E. Accuracy and reliability of pulse oximetry at different arterial carbon dioxide pressure levels	sectional	3		Stable patients with chronic lung disease (74.2% COPD) undergoing LTOT assessment		SpO2 vs SaO2 correlation at differing CO2 levels		Agreement between SpO2 and SaO2	SpO2 overestimated SaO2 at elevated CO2 levels (ie >6,40kPa). Agreement between SpO2 and SaO2 also poor when PaO2 low (ie <7.20kPa)	Nil declared
40 Zavorsky et al 2007	Metaanalys is	1+	CBG hypoxic group (ie PaO2<70mm Hg) and 227 in earlobe CBG	patients including healthy controls, healthy controls under	and earlobe	ABGs vs fingertip CBGs. ABGS vs earlobe CBGs		Accuracy of CBGs using ABGs as gold standard	Mean difference and 95% confidence intervals for a) fingertip - arterial: overall 10.4mmHg (8.4-12.4); hypoxia 3.1mmHg (1.8-4.4) b) earlobe - arterial: overall 2.4mmHg (1.9-2.8); hypoxia 0.7mmHg (0.3- 1.1)	Nil declared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
41 A D Pitkin, C M Roberts, J A Wedzicha. Arterialised earlobe blood gas analysis: an underused technique. Thorax 1994;49:364-366	Prospectiv e observation al cross sectional study		40	Patients with chronic lung	Simultaneous radial ABG and arterialized earlobe capillary sample	ABG vs CBG	assessment	between ABG and CBG with respect to PaO2, PaCO2 and pH	CBG vs ABG PaO2 (mean difference -0-17, 95% confidence intervals - 1 09 to + 0 75 kPa)	Nil declared
42 Schafroth Tarok et al. Combined oximetry- cutaneous capnography in patients assessed for long term oxygen therapy	Before- After study	3		Chronic lung disease with PaO2<55mH or <59 in presence of pulmonary hypertension	Oxygen at variable flow rates to obtain SaO2>90%	None	study	between arterial	Minimal bias between PtCO2 and PaCO2	Undeclared

44 Pilling, J.; Cutaia, M Ambulatory oximetry monitoring in patients with sepretable and preliminary study 1999  Before-After study  Besponse to chamces in chamce study  Besponse to CO2 stimulation  COPD patients with supplementation on COPD patients with supplementation on COPD patients with special study  Besponse to chamces in chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with supplementation on COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to chamces in COPD patients with special study  Besponse to COPD patients with special study  Besponse to COPD patients with special study  Bespon	3 Chiang et al. espiratory response to arbon dioxide stimulation uring low flow upplemental oxygen lerapy in Chronic abstructive Pulmonary isease  4 Pilling, J.; Cutaia, M mbulatory oximetry ponitoring in patients with selected positions or and in patients with ponitoring in patients with selected positions or an experience of the patients with supplemental oxygen lerapy in Chronic arbon dioxide stimulation uring low flow upplemental oxygen lerapy in Chronic arbon dioxide stimulation on a supplemental oxygen lerapy in Chronic arbon dioxide stimulation on a supplemental oxygen levels in corporation in chemoresponsi veness in COPD patients with normocapnoea vs hypercapnoea  4 Pilling, J.; Cutaia, M mbulatory oximetry ponitoring in patients with severe COPD: a reliminary study 1999  4 Pilling study Saygen and sessesment study  Assessment study  Assessment study  Assessment study  Assessment study  Hypercapnoeic patients with seponse to CO2 stimulation  COPD patients with normocapnoea vs hypercapnoea  Nil single test study  Will single test study  Assessment study  Hypercapnoeic patients with seponse to CO2 stimulation  Hypercapnoeic patients with seponse to CO2 stimulation  Hypercapnoeic patients sudy  Hypercapnoeic patients with seponse to CO2 stimulation  Hypercapnoeic patients with seponse to CO2	Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
Ambulatory oximetry nal LTOT ambulatory SpO2 whilst 25% of their ambulatory severe COPD: a preliminary study 1999 LTOT ambulatory study 1999 with SpO2	mbulatory oximetry nal LTOT ambulatory SpO2 whilst 25% of their ambulatory time with Sp02   ambulatory oximetry nonitoring in patients with evere COPD: a reliminary study 1999 monitoring ambulatory whilst ambulatory ambulatory with Sp02<90%	43 Chiang et al. Respiratory response to carbon dioxide stimulation during low flow supplemental oxygen therapy in Chronic Obstructive Pulmonary Disease		3	26	Stable COPD patients with varying severity	supplementati	chemoresponsi veness in COPD patients with normocapnoea vs			patients demonstrate blunted response to CO2	Undeclared
Ambulatory oximetry nal LTOT ambulatory SpO2 whilst 25% of their ambulatory severe COPD: a preliminary study 1999 LTOT ambulatory study 1999 with SpO2	mbulatory oximetry nal LTOT ambulatory SpO2 whilst 25% of their ambulatory time with Sp02   ambulatory oximetry nonitoring in patients with evere COPD: a reliminary study 1999 monitoring ambulatory whilst ambulatory ambulatory with Sp02<90%											
		44 Pilling, J.; Cutaia, M Ambulatory oximetry monitoring in patients with severe COPD: a preliminary study 1999 Chest 314-20		3			ambulatory SpO2	Nil	-	saturating <90% whilst	patients spent 25% of their ambulatory time	undeclared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
46 Silwinski et al. The adequacy of oxygenation in COPD patients undergoing long term oxygen therapy assessed by pulse oximetry at home	Observati onal	3	34	Stable COPD on LTOT	24 hr SaO2 monitoring on LTOT	Nil		% time spent saturating <90%	On average patients spent 6.9hrs with Sa02<90%	Undeclared
47 Abdulla, J.; Godtfredsen, N.; Pisinger, C.; Wennike, P.; Tonnesen, P. Adequacy of oxygenation in a group of Danish patients with COPD on long-term oxygen therapy. Monaldi Archives for Chest Disease. 2000. 54, 4, 279-82	Case series	3	26	COPD on LTOT	24hr pulse oximetry with activity diary		Single measure	Mean saturation	Mean SpO2 over 24hrs on LTOT was acceptable at 94%, with only minimal episodes of desaturation	Undeclared
48 Zhu et al (2005) Continuous oxygen monitoringa better way to prescribe long- term oxygen therapy. Respiratory Medicine. 1386-1392	Cohort	2-	17	Stable COPD on LTOT	O2 flow adjusted to maintain SpO2 88- 92%using 24hr SpO2 monitoring	Initial vrs altered O2 flow		Time spent outside target SpO2	28% increase in time within target saturation (p=0.001)	Undeclared

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
49 Morrison D, Skwarski K Macnee W. resp Med 1997;91;287-291	Observatio nal study	3	20	Stable COPD patients already receiving LTOT at prescribed flow rate		Correlation between continuous pulse oximetry and single ABG on current oxygen flow rate	over 24 hours	oxygen provision comparing single ABG to continuous pulse oximetry	not achieve adequate oxygenation when	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
50 Nisbet et al.  Overnight prescription of oxygen in long term oxygen therapy: time to reconsider the guidelines?	Observati	3	38	stable COPD on LTOT	Overnight oximetry on usual LTOT flow rate	Nil		No. of patients who desaturating <90% for >30% of the night	16% desaturated significantly	undeclared
Sliwinski, P.; Nowinski,	Case control study	2-	82	COPD on LTOT	nocturnal oximetry		single test		47.6% of patients desaturated significantly overnight on LTOT	undeclared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
52 Peckham et al Improvement in patient compliance with long-term oxygen therapy following formal assessment with training 1998 Respiratory medicine 1203-06	Non- randomise d controlled trial	2+	86	Patients with chronic respiratory disease prescribed LTOT	on two	Formal assessment + education by Respiratory specialist vs GP prescription with no education	Š	prescription - self reported and clock time. Patient understanding.	82% vrs 44% using LTOT for 15hrs min (p=0.002). 93% understood rationale for treatment vs 41%	Undeclared

Source Provided to the Provided Residual Services of the Properties of the Provided Residual Services of th

Bibliographic citation	Study type	level	No patients	Patient characteristic	intervention	Comparison	Length of f/u	measures	Effect size	Funding
53. Pepin J-L, Barjhoux CE, Deschaux C, Brambilia C, on behalf of the ANTADIR Working Group on Oxygen Therapy. Chest. 1996;109:1144-1150. Long-term Oxygen Therapy at Home Compliance with medical prescription and effective use of therapy.	Non-comparative study	2-		s chosen randomly from LTOT registers in 14 ANTADIR regions. COPD. Aged 40-80. Those on NIV & CPAP excluded	patient review at home and questionnaire to prescribing physician	None	Nil	Oxygen uasge	3 1	CNMRT special fund contract 90 MR/16

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
54 Eaton, T.; Rudkin, S.; Garrett, J. E 2001 An evaluation of shrt term oxygen therapy: the prescription of oxygen to adults with chronic lung disease hypoxic at discharge form hospital. Respiratory Medicine 95 (8) 655-60	Observati onal	3	160	Referrals for LTOT assessment - mixed disease group	LTOT assessment	Those who met criteria for LTOT and those who did not		Standard measures for LTOT PaO2<7.3kPa or 8kPa if added problems	47.5% of all acute inpatient referrals required LTOT at 2 months. 30% of those given O2 at discharge did not meet criteria for LTOT at 2 months (include drop outs/deaths on intention to treat 25%)	Undeclared
55. Cottrell JJ, Openbrier D, Lave JR, Paul C, Garland JL. Chest. 1995;107:358-361. Home Oxygen Therapy a comparison of 2- vs6-Month Patient reevaluation	Cohort Study	2-	50	patients who met LTOT criteri and had 6 months experience of LTOT. Stable for at least the 6 weeks before enrollment. Able to give informed consent.		6 monthly follow-up		VAS score,	Evaluation costs were significantly lower (p<0.001) in 6 monthly follow up group.	VA grant 87-033, NHLBI grant T32 HL07563, and the American lung Association of Pennsylvania

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	-	characteristic		-	_	measures		
	7.			s						
56.Granados A, Escarrabill J, Borras JM, Rodrigues-Roisin R. Respiratory Medicine. 1997;91;89-93. The importance of process variables analysis in the assessment of long term oxygen therapy by concentrator.	Non- comparativ e study	2-	62	Random sample of 111patients who received LTOT via concentrator in Catalonia (Spain) during 1991. Those who had died or were no-longer on LTOT were excluded	patient interviews at home	No comparison		concentrator and hours of usaage. FiO2 produced,	LTOT criteria at	Nil reported
57.Godoy I, Tanni ST, Hernandez C, Godoy I. Int Jour COPD. 2012;7:421- 425. The importance of knowing the home conditions of patients receiving long-term oxygen therapy.	Non- comparativ e study	3	97	patients who met LTOT criteria and had used it for 6 months(brazilian criteria i.e. pO2 <55mmHg or SpO2<88%. Or pO2 between 56 and 59mmHg or SpO2 89% with evidence of pulmonary hypertension, peripheral oedema or polycythaemia	Patient interviews at home	No comparison		SpO2 on LTOT and after 20 mins on air, compliance with prescription	62% patients required concentrator maintenance, 85 required smoking cessation advice, 5% required tubing replacement or adjustment.	Nil reported

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
58.Rizzi M, Grassi M, Pecis M, Andreoli A, Taurino AE, sergi M, fanfulla F. Arch Phys Med Rehabil. 2009. ;90:395- 401.	cohort	2+	217	COPD out- patients who had been on LTOT for at least 1 year, were stable and on optimal therapy at inclusion but had at least 1 exacerbation the preceding year. Enrollment From 1st Jan 20014 to	clinical and functional evaluations every 6 months with domiciliary assessments by specific team of (pneumologist, respiratory nurse and			demographics, charlston Index, exacerbation frequency, intubations and survival.	survival in homecare group was better than standard care p=0.0001. Need for NIV was reduced in the Homecare group p=0.005, need for intubation was 7.3% lower in the homecare group (p=0.08), emergency department visits decreased in homecare compared with standard care p=0.009	Nil reported

Bibliographic citation	Study		No patients	Patient	Intervention	Comparison	Length of f/u		Effect size	Funding
	type	level		characteristic				measures		
59. Farrero E, Escarrabill J, Prats E, Maderal M, Manresa F. Chest. 2001;119:364-369. Impact of a hospital based homecare program on the management of COPD patients receiving longerm oxygen therapy.	RCT	1-	122	primary diagnosis of COPD and meeting LTOT criteria, at least 6 months experience on LTOT, able to travel to hospital sites.	monthly phone call, hospital visits every 3 months and home or hospital visits on demand	medical care.	·	demographics, CRDQ, hospital resource use, costs of resources	Home care group had signif decreased use of ED compared with controls p=0.0001, significantly less admissions to hospital p=0.001 and and significantly less hospital days p=0.01. costs were reduced by \$46,214 in Homecare group	Nil reported
60. Goldbart J, Yohannes AM, Woolrych R, Caton S. Health and Quality of life Dutcomes. 2013;11:124- 132. 'It is not going to change his life but it has bicked him up': a qualitative study of perspectives on long-term boxygen therapy for people with Chronic Obstructive bulmonary disease.	Non- comparativ e study	3	carers and 9	COPD patients on LTOT in single PCT who returned initial questionnaires and consented to take part in focus groups	3 Focus groups	None		Qualitative info on: Impact of living with COPD and views of LTOT service		NHS Wirral

1/12/2014

Bibliographic citation	Study type	Evidence level	•	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
61. Restrick LJ, Paul EA, Braid GM, Cullinan P, Moore-Gillon J, Wedzicha JA. Thorax. 1993; 48:708- 713 Assessment and Follow-up of patients prescribed long-term oxygen treatment	Non- comparativ e study	2-	176	All patients who had static concentrators in 3 GP authorities on 1st January 1991	Review at home	None		demographics, ABG's, problems with LTOT	74% patients used oxygen for > 12 hours. 46% of patients with SpO2. 91% met LTOT criteria	Nil reported
62 A randomized trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease patients. Chaouat, A.; Weitzenblum, E.; Kessler, R.; Charpentier, C.; Enrhart, M.; Schott, R.; Levi-Valensi, P.; Zielinski, J. Eur Respir J 1999; 14(5); 1002-8	RCT	1+		COPD with mild daytime hypoxia (PaO2 7.4-9.2kPa) and nocturnal desaturation (>30% night with O2 sats <90%). OSA excluded.	NOT aiming for SaO2>90% - usually 2l.min nasal cannulae	NOT or air	,	(Rt heart	No significant difference in survival, time to LTOT, pulmonary haemodynamics	Grant from Programme Hospitalier de Recherche Clinique
63 Mckeon J, Murree-Allen K, Saunders N. Thorax 1989:44: 184-8 Supplemental oxygen and quality of sleep in patients with chronic obstructive lung disease.	RCT	1+		14/23 male, 4 smokers, mean PaO2 at rest 7.7 (5.5-10.9)	NOT titrated to maintain O2 sats>90% or compressed air nasal cannulae	NOT or air	-	PSG and sleep questionnaire	No difference in sleep quality	grant from NHS and MRC

1/12/2014

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
64 Survival in COPD patients with a daytime PaO2 greater than 60mmHg with and without nocturnal oxyhaemoglobin desaturation. Fletcher EC, Donner CF et al. Chest 1992 Mar: 101 (3): 649-55	Cross sectional study	2+	169	S COPD, some smokers, PAO2>60mmHg and evidence of nocturnal desaturation in REM sleep for minimum of 5 mins to <85%	varied - 5 centres - no details given	NOT or air	survival study	Survival differences between nocturnal desaturators and non- desaturators, and between those receiving NOT and no	signficinatly better on those without nocturnal	None declared
65 A Double-blind Trial of Nocturnal Supplemental Oxygen for Sleep Desaturation in Patients with Chronic Obstructive Pulmonary Disease and a Daytime PaO2 above 60mmHg Fletcher EC et al Am Rev Respir Dis 1992; 145: 1070-1076	RCT	1+	29	COPD with daytime PaO2>60mmHg (O2 sats >90%), evidence of nocturnal desaturation during REM sleep. Some smokers	nasal O2 at 3 l/min (confirmed that corrected desaturation)	compressed air at 3l/min nasal	Š	, polysomnograph	Reduction in PA pressures of - 3.7mmHg over 3 yrs. No signficant difference in other parameters	None declared
66 Effects of oxygen therapy on left ventricular function in patients with Cheyne-Stokes respiration and congestive heart failure. Krachman, Samuel L.; Nugent, Thomas; Crocetti, Joseph; D'Alonzo, Gilbert E.; Chatila, Wissam. Journal of Clinical Sleep Medicine 2005; 1 (3): 271-6		1-	10	CHF LVEF < 12%, AHI 57+/- 61/hr,	NOT nasal cannulae 2l/min or air	NOT or air	30 days	AHI and sleep quantity and quality, radionucleotide	NOT reduced AHI after 1 night and had same effect size at 30 days. NOT showed no change in LVEF, sleep time and sleep architecture.	

1/12/2014

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
67 Javaheri, S.; Ahmed, M.; Parker, T. J.; Brown, C. R. Sleep 22(8): 1999; 1101- 6. Effects of nasal O2 on sleep-related disordered breathing in ambulatory patients with stable heart failure	Non randomise d controlled trial	1-	36	<45%, Sleep study AHI >15/hr	cannuale 2-	NOT or air		AHI, ABG, cardiac radionuclide ventriculography and holter monitor for	NOT significantly reduced total AHI in 41% patients (mainly reducing central sleep apnoea index) but did not affect total sleep time	None declared
68 Hanly PJ, Millar TW, Steljes DG, Baert R, Frais MA, Kryger MH. Annals Int Med 1989;111:777-782. The Effect of Oxygen on Respiratory and Sleep in patients with Congestive Heart Failure.	RCT	1+	9	HF NYHA 3/4, LVEF <30%, awake O2 sats	NOT nasal cannuale 2- 3l/min or compressed air via nasal cannuale	NOT or air		PSG to measure CSR, sleep quality, AHI, total sleep time	increased total	Part funded by Heart and Stroke Foundation of Canada and MRC Canada

			characteristic s		Comparison	Length of f/u	measures		Funding
RCT	1+	11	Stable heart failure with LVEF <40%. Baseline PaO2 was 10.7KPa	4 week periods of overnight oxygen 2l/min nasal cannulae or air (blinded using sham concentrators)	overnight oxygen and air		neuroendocrine tests (noradrenaline,	nocturnal HOT group showed reduction in CSAs, no effect on OSAs, no effect on patient symptoms or cognitive function, reduced urinary noradrenaline concentration	not declared
RCT	1+		LVEF <30%,	or	NOT or air	Č	test, baseline echo, spirometry, symptom	NOT significantly reduced CSR, total sleep time and quality, peak O2 consumption during exercise test and test for cognitive function but not daytime symptoms	None declared
	CT	CT 1+	CT 1+ 22	CT 1+ 22 Severe HF, LVEF <30%,	Total design and the second se	Total design and the second of	Total design of the second of	To the set of the set	10.7KPa  nasal cannulae or air (blinded using sham concentrators)  The state of cannulae or air (blinded using sham concentrators)  The state of cannulae or air (blinded using sham concentrators)  The state of concentration  The state of cannulae or air (blinded using sham concentrators)  The state of concentration  The state of concentration or cognitive function, reduced urinary noradrenaline concentration  The state of concentration  The state of concentration  The state of concentration or cognitive function, reduced urinary noradrenaline concentration  The state of concentration or cognitive function or cognitive function, reduced urinary noradrenaline concentration  The state of cognitive function or cognitive function of the state of cannulae or air of cognitive function or

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
71 Sasayama S, Izumi T, Matsuzaki, M.; Matsumori, A.; Asanoi, H.; Momomura, S.; Seino, Y.; Ueshima, K.; Circ J 2009;1255-1262Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea.	RCT	1-	51	HF (NYHA II-III) and CSA. Baseline PaO2 not given.	overnight oxygen 3 l/min nasal cannulae or usual breathing	overnight oxygen and air		QOL (Specific activity scale), ventricular function (ejection fraction), SDB indicators (PSG), plasma concentration neuropeptides	HOT group showed significant improvement in SDB indicators, SAS, and NYHA class. No signficant improvement in LV function or plasma neuropeptide levels.	Teijin Pharma Ltd, Tokyo
72 Brostrom A, Hubbert L, Jakobssen P, et al J Cardiovascular nursing 2005: 20(6); 385-396. Effects of long etrm nocturnal oxygen treatment in patients with severe heart failure	case series	3	22	HF (NYHA III/IV)	NOT at 2I/min for 10 hrs	pre and post NOT compairing outcomes for AHI> and < 20		PSG, Echo, 6MW, Sleep questionnaire and ESS, HRQOL	Significant improvement in 6mw in all patients. No change in cardiac function, sleep quality, HRQOL	Swedish Foundation for healthcare science and allergy research grant
73 Suzuki, Jun-ichi; Ishihara, Takashi; Sakurai, Kaoru; Inagaki, Hiroshi; Kawabata, Mihoko; Hachiya, Hitoshi; Hata, Akihiro; Circulation journal 2006; 70 (9): 1142-7. Oxygen therapy prevents ventricular arrhythmias in patients with congestive heart failure and sleep apnea	Non randomise d controlled trial	1-	37	HF adult	NOT 3l/min nasal cannulae	NOT or air		Holter monitoring, PSG, echo, BNP	Group with lower daytime O2 sats and frequent PVCs had no change in PVCs or heart rate with NOT compared to group with normal daytime sats and fewer PVCs	Japan Cardiovascular research foundation

Bibliographic citation		Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
74 Paul B, Joseph M, Pasquale CG. Hert, Lung, Circulation 2008; 17:220- 223 Domicilary Oxygen Therapy Improves Sub- maximal Exercise capacity and quality of life in Chronic Heart failure.	case series	3		8Male, 2 female, HF LVEF < 40%,		NOT	4 weeks	6 min walk, echo, QOL score, Biological marker (NTproBNP),	improvements in	Funded by National Heart Foundation Australia
75 7' D. C M	DCT	4.	20	CF and in the	Nectorial	LTOT		Adama	Calcada	Constitution CE
75 Zinman R, Corey M, Coates AL, Canny GJ, Connolly J, Levison H, Beaudry PH. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 1989;114(3):368-377.	RCT	1+		CF patients with PaO2 <65mmHg and stable. All with PaCO2 >60mmHg were excluded	1 litre increasing increments	LTOT versus room air		Admission frequency. Death. Disease progression (measured by BMI, pulmonary function, exercise capacity and RV ejection response to exercise)	School and work attendance was maintained in not versus air group. No effect on mortality/admis sion or disease progression measures	Canadian CF foundation

76 Spier S, Rivlin et al. The effect of Oxygen on Sleep, Blood Gases and Ventilation in Cystic Fibrosis	Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
ventilatory support in patients with cystic fibrosis: compariosn with supplemental oxygen  d controlled trial, non blinded  29% pred, 2 had daytime hypercapnia  29% pred, 2 had daytime hypercapnia  BIPAP and BIPAP and BIPAP and CO2, lung function  BIPAP using nasal mask  Supplemental oxygen  Supplement	76 Spier S, Rivlin et al. The effect of Oxygen on Sleep, Blood Gases and Ventilation in Cystic Fibrosis	d controlled			Adult CF FEV1 < 25% pred, awake SaO2 <92%, 4 had daytime	oxygen or compressed air delivered via nasal			y, tidal volumes, transcutaneous	oxygen saturation improved, TcPCO2 rose but not to clinically significant degree, no change in no of arousals or Ither sleep	None declared
	77 Gozal D. Nocturnal ventilatory support in patients with cystic fibrosis: compariosn with supplemental oxygen	d controlled trial, non	=	6	29% pred, 2 had daytime	oxygen titrated (not clear to what level) or BIPAP using	BIPAP and		y, transcutaneous CO2, lung function	NOT improved oxygenation but no changes in sleep quality. 2 patients had sym,ptomatic rises in PTCCO2 which was improved with	None declared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
78 Milross, M. A.; Piper, A. J.; Norman, M.; Becker, H. F.; Willson, G. N.; Grunstein, R. R.; Sullivan, C. E.; Bye, P. T. P. American Journal of Respiratory and Critical Care Medicine. 2001; 163 (1); 129-134. Low-flow oxygen and bilevel ventilatory support: Effects on ventilation during sleep in cystic fibrosis	RCT	1+	13	Adult CF, FEV1<65% pred, awake PaO2 53- 77mmHg	Air with CPAP at 4cmH2O, NOT with CPAP at 4cmH2O titrated to maintain O2 sats>90%, BiPAP and NOT titrated to maintain O2 sats>90% and prevent hypercapnia	Air or NOT or BiPAP with NOT	3 nights	Lung function, ABG, PSG, Ventilation via pneumotach	Vi (minute ventilation) was reduced on Air and NOT nights in REM sleep, but not with BIPAP+NOT, which also prevented rise in TcCO2: a significant CO2 rise and fall in pH was seen with NOT alone. Total sleep time less on BIPAP than NOT or air.	None declared
, , ,	Non- randomise d controlled trial	1-	33	Adults ILD patients (mixed types of ILD) living at moderately high altitude	nasal prongs	Air or NOT	2 nights	breathing frequency, heart rate, sleep study indices	reduction in heart arte and breathing frequncy with oxygen. No effect on sleep quality	Supported by "CONACYT and INER"
80 Smith PEM,Edwards RHT, Calverley PMA. Oxygen treatment of Sleep Hypoxaemia in Duchenne Muscular Dystrophy	d controlled	1+	7	Adult patients with Duchenne muscular dystrophy FVC 1.37L and normal daytime ABG	room air, nasal cannulae oxygen at 2l/min	Air, NOT,		y, lung function.	Compared with air Not reduced sleephypoxaemia but prolonged episodes of hypoventilaton and apnoeas and had no effect on arousals	Muscular Dystrophy Group

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
82 Bradley et al. The Cochrane Database 2005 Issue 2	Metaanalys is	1+	469	COPD patients with moderate to severe airflow obstruction - including both those who fulfilled criteria for LTOT and those who did not	Single assessment studies studying beneficial effects of oxygen during exercise testing	Oxygen vs cylinder air	assessment	Endurance and maximal exercise capacity	Improvements in all outcomes relating to endurance (distance, time and number of steps).	N/a
83 Judy M. Bradley, Toby Lasserson, Stuart Elborn, Joe MacMahon, and Brenda O'Neill, A Systematic Review of Randomized Controlled Trials Examining the Short term Benefit of Ambulatory Oxygen in COPD* (CHEST 2007; 131:278–285).	Systematic Review of RCT's - single assessmen t studies	1++	534	COPD, mean age 47-73, mod-severe obstruction (1 study mild) mean resting pa02 = 6.9 to 11.3. Various dose of oxygen	performance during a single exercise test using ambulatory oxygen	ambulatory oxygen vs placebo air		exrecise capicy (distance or time), dyspnoea scores BORG/VAS, sa02 (pulse oximetry or ABG's)	exercise distance by 18.86 m (95% CI 13.11-24.61 m, n=238) exercise time increased by 2.71 mins (95% CI =1.96 -3.46 min, n=77)	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
84 Nonoyama et al Cochrane database 2007 Issue No. 2	Metaanalys is	1-	63	COPD patients who did not fulfill criteria for LTOT		Oxygen vs air	training for ≥3 weeks, including ≥2 sessions per week	Exercise time, Exercise distance, oxygenation status, Borg scores and HRQL	Increased constant power exercise time (2.68 minutes) and improved Borg scores (- 1.22 units) but no improvement in 6MWD, shuttle walk distance, HRQL or oxygenation status	n/a
85 Dyer et al. Chronic Respiratory Disease 2012 9:83	Single blinded RCT	1-		COPD patients attending PR who had demonstrable desaturation and who had previoulsy been noted to walk further with supplemental oxygen	Supplemental oxygen use during the exercise-training component of a PR programme	Oxygen vs cylinder air		Endurance shuttle walk test, quality of life	490m (95% CI 228-750) improvement in ESWT. No signficant change in quality of life	

	o Air = 75, o 02 = 68	previous oxygen, no rehab,stable,no locomotor disease. 50 were classed as desaturators <88% after 6MWT moderate to severe COPD mean FEV1 =	amb oxygen cylinder to use inside and outside during exertional	to use inside and outside	reassessed then randomised, measures repeated at 4 weeks and end of study 12	PFT's,CRDQ, 6MWD,BDI, AQoL, HADS, activity count (pedometer)		National Health and Medical Research Council, Northern Clinical Research Centre, Victorian Tuberculosis and
		1.16 (0.51)			weeks			Lung Association, Austin Hospital Medical Research Foundation, Institute for Breathing and Sleep, Austin Hospital, Australia Finkel Foundation, Air Liquide, Boehringer Ingelheim.
1-		COPD patients who did not fulfill	,	Oxygen vs cylinder air			Improvements in all domains of CRQ, in HAD and in some domains of SF-36	n/a
1-			COPD patients	COPD patients ambulatory who did not fulfill oxygen	COPD patients ambulatory cylinder air who did not fulfill oxygen	COPD patients ambulatory cylinder air who did not fulfill oxygen	COPD patients ambulatory cylinder air SF-36 who did not fulfill oxygen	COPD patients ambulatory cylinder air SF-36 all domains of CRQ, in HAD and criteria for LTOT some domains

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
90 Nonoyama et al. AJRCCM 2007 176:343-9	Individual blinded RCT ('n of 1')	3	27	COPD patients who do not fulfill requirements for LTOT	Domiciliary ambulatory oxygen for 2 week periods	Oxygen at 2L/min vs cylinder air		5 minute walk test, CRQ and SGRQ	Significant improvement in 5MWD (427 steps vs 412 steps) but no difference I CRQ or SGRQ	n/a
91 Sandland et al Chest	Double	1-	20	COPD patients	Domicilary	Oxygen vs	8 weeks	Total domestic	No change in	
2008; 134:753-760	binded RCT			who were either hypoxic at rest or who desaturated on exercise	oxygen or cylinder air for 8 weeks	cylinder air		activity and HRQOL	domestic activity or HRQL between groups	
91 Ringbaek et al. 2013 Chronic Respiratory Disease 10(2);77-84	Unblinded RCT	1-	45	COPD patients who are normoxic at rest but who desaturate	Domiciliary ambulatory oxygen during 20 week PR programme	Oxygen at 2L/min vs control (ie room air)	(including 20	ESWT, SGRQ, exacerbation rate or hospital admission rate	No differences	
93 McDonald, C.F, Blyth,C.M, Lazarus, M.D, Marschner, I, Barter, C.E. Exertional Oxygen Of Limited Benefit in Patients with Chronic Obstructiive Pulmonary Disease and Mild Hypoxemia. 1995. Am J Resp Crit Care Med 152 pp1616-1619.	RCT - crossover. Blinded	1++	26	stable COPD MOD-SEVERE pa02>60 mmHg	6 weeks of amb cylinders or 6 weeks of amb air cylinders	airs vs oxygen amb cylinders provided for home and outdoor use		PFT's, 6MWD, step test, diary symptom cards, CRDQ		Sir Edward Dunlop Research Foundation and Medical Gaes, Australia.

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
95 Vergeret et al 1989 ERJ 2:20-25	Unblinded RCT	1-	159	COPD patients who met criteria for LTOT	LTOT via concentrator alone or via concentrator + AOT or liquid oxygen	LTOT via concentrator alone or via concentrator + AOT or liquid oxygen	12 months	Daily use of oxygen.	Patients with a concentrator and AOT or liquid oxygen accumulated greater daily use (17 hours/day vs 14 hours day)	n/a
95 Vergeret, J.; Brambilla, C.; Mounier, L.: Portable oxygen therapy: use and benefit in hypoxaemic COPD patients on long- term oxygen therapy: 1989 The European respiratory journal: 20- 25	RCT	+	122 tl1e number of medical check-ups and home questionnair es was 158 at 3 months, 136 at 6 months, 128 at 9 months and 122 at 12 months (58 with fixed oxygen, 64 with portable oxygen).	Stablse 40 - 75 year old severe COPD patients with a PaO2 < 8kPa but > 5.3kPa and PaCO2 < 8.2 kPa already receiving LTOT snd able to walk 200m on 12 min walk test	12 centre study with no analysis of separate centre data although don't think this would make a difference. Might have been useful to look at the concentrator patients when loaned portable systems to see if compliance did improve	Liquid oxygen compared with ambulatory cylinder/conce ntrator		Cost and QOL (daily duration of use and daily activity)	Care, held December 13- 16, 2008, in Anaheim, California. Thesymposium was made possible by an unrestricted educational grant from Boehringer Ingelheim.	Care, held December 13- 16, 2008, in Anaheim, California. The

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
96 Lacasse et al 2005; 25:1032-8	Randomise d crossover trial			COPD patients who met criteria for LTOT	LTOT via concentrator alone or via concentrator + AOT vs cylinder air	LTOT via concentrator alone or via concentrator + AOT vs cylinder air		6MWD, CRQ and daily use of oxygen	benefit from AOT - study stopped	Quebec universal medical insurance plan
97 Casaburi et al 2012 COPD 9(1):3-11	Unblinded RCT	3	22	COPD patients who met criteria for LTOT	Standard' cylinder (weighing 22lb) carried via cart vs 'lightweight' (weighing 3.6lb) cylinder	Standard' cylinder (weighing 22lb) carried via cart vs 'lightweight' (weighing 3.6lb) cylinder		(as measured by	No difference between groups in activity levels	n/a

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic		-		measures		
				s						
97 Casaburi, Richard;	RCT	+	22	Male/femal >=	Does a	Comparing a	Baseline	Used a	Activity and	COPD clinical
Porszasz, Janos; Hecht,			randomised	40 stable	lightweight	lightweight	activity and	conserving	oxygen	research
Ariel; Tiep, Brian; Albert,			17	COPD (FEV1 <=	cylinder	portable	oxygen use	regulator	utilisation was	networkby a
Richard K.; Anthonisen,			completed	60%) patients	improve	cylinder with		capable of	analysed. Static	
Nicholas R.; Bailey,					oxygen use	standard		measuring O2	and ambulatory	_
William C.; Connett,				established on	= . • .	ambulatory		use for	data were	from the
John E.; Cooper, J.				ITOT who had	patients	cylinder plus	during which	ambulation.	merged.	National Heart,
Allen, Jr.; Criner,				no ambulatory		compliance	•	Stationary O2	Stationary and	Lung and Bloo
Gerard J.; Curtis,				source or just		over a period			ambulatory use	institute. No
Jeffrey; Dransfield,				an E cylinder		of time (this	cylinder.	tracker" a		commercial
Mark; Lazarus, Stephen				an L cyllinder		included a	Then patient	piezoelectric	24 hours per	sources were
C.; Make, Barry;						static	randomised.	sensor to	day and the	utilised.
Martinez, Fernando J.;						concentrator)	Activity was	record	average	
McEvoy, Charlene;							monitored for	pressure	calculated. Satn	
Niewoehner, Dennis E.;							3 weeks	fluctuation,	measured on	
Reilly, John J.; Scanlon,							before and 3	attached to a	patients with	
Paul; Scharf, Steven M.;							and 6 months	standard	ambulatory and	
Sciurba, Frank C.;							at centre	concentrator.	statie giving	
Woodruff, Prescott;							visists. 42	How often/how	SpO2 =>92%.	
Copd Clinical Research							days of home	many hours	Patients only	
Network. Influence of							recording	theambulatory	averaged 2.5	
lightweight ambulatory							with static	device was	hours per day	
oxygen on oxygen use							concentrator	used.	using E cylinder	
and activity patterns of								Recorded by	and activity level	
COPD patients								electronic	was very low.	
receiving long-term								device	Not improved by	
oxygen therapy. Journal									using a light	
of Chronic Obstructive									weight cylinder.	
Pulmonary Disease.									Questionnaire	
2012. Pages 3 -11									used for patients	
									to estimate	
									compliance.	

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	-	characteristic		-		measures		
				s						
O Journal of pain and	Randomize d double blind cross over trial	2+		over the age 18 with diagnosis of cancer who complained of dyspnoea with a dyspnoea intensity score of	randomized to receive eith air or oxygen at 4 litres / min via nasal cannula for 15 minutes	impact of		VAS for dyspnoea, QLQ- C30 dyspnoea measurement, Dyspnoea assessment questionnaire results and pulse oximetry, pre and post blinded administration of oxygen and air at 4 litres. The preferred as was then nominated.	No significant difference identified in VAS or QLQ-C30 for 2 gas types, oxygen saturations showed improvement in oxygen arm of study however there was no evidence of a significant correlation between VAS score and oxygen saturation. No significant gas preference for oxygen over air, 41% expressing a preference for oxygen, 29% a preference for air and 29% no preference.	Australian New Zealand Society of palliative care
							r			
		1		I .	1	i	1.	i e	I .	1

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
107 Abernathy A McDonald C Frith P Clark K Herndon J Marcello J Young I Bull J Wilcock A Booth S Wheeler J Tulsky J Crockett A Currow D 2010 lancet 376:sept 4	Randomize d double blind cross over trial	1+	239	Patients over age of 18 with life limiting illness who did not meet criteria for LTOT (PaO2 more than 7.3kPa) who are on optimum medication but experience refractory breathlessness (MRC 3 or greater)	of oxygn or air at 2 litres continuously via concentrator for relief of	Breathlessness rating recorded twice daily, daily diary recording of average dyspnoea expeieinced in previous 24 hours following administration of oxygen or air via concentrator 15 hours /day, and side effects reported by use of likert 5 point scale.		breathlessness right now twice daily, Numerical rating scale recorded in diaries for previous 24 hour period. Daily QoL questionnaire, Modified MRC and 5 point likert scale for side effects.	breathlessness noted in either group. 52% patients on oxygen and 40% patients on air responded to intervention with morning dyspnoea and 42% of patients in both groups	US National institute of Health, Australian National health and Medical research counci Duke Institute.
108 Uronis HE, Currow DC, McCrory DC, Samsa GP and Abernethy AP. British J of Cancer (2008) 98, 294-299	Systematic review of RCTs	1+	134	Adult cancer patients with refractory breathlessness not qualifying for home LTOT.	effect of oxygen and medical air on dyspnoea. Oxygen was delivered by nasal canula in 3 studies,	comparing oxygen and medical air		Assessment of breathlessness using VAS, NRS or Modified Borg		Not stated

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
• .	type	level	-	characteristic		-		measures		
				s						
109 Clemens K Quednau I Klaschik E 2009 Support Care Cancer 17;367-377	prospective non randomise d study	2+	46	adult inpatients on palliative care unit with advanced cancer or other terminal incurable disease and had dyspnoea at rest. Patients with Hb <10 were excluded	4 L/min applied at rest for 60 min. Additionally Opioids were given as per the intensity of	patients on room air, 60 minutes after oxygen delivery compared with data obtained at regular intervals	of dyspnoea, SaO2, tcpaCO2, pulse rate and resp rtae for 15 min breathing room air at admission, 60 min during	ventilation and relief of dyspnoea in hypoxic and non-hypoxic palliative care patients either opioid naive or pre treated with strong opioids.	significantly better than oxygen in reducing the intensity of dyspnoea even in hypoxix patients.	Not stated

type level characteristic s 110 Currow D Agar M Smith J Abernathy A 2009 Palliative med 23;309  Cohort study  5862  Adult patients with cancer and other life limiting illness oxygen. Patient rated symptom assessment scale so prescribed oxygen. Patient rated symptom assessment scale for each clinical contact in the community but could not include pulse oximetry.  Symptom assessment scale so 2 weeks pre initiation of broathlessness at baseline and 1 or two weeks post oxygen of therapy.  Who clinically significant improvement on breathlessness at baseline and 1 or two weeks post oxygen on 2 weeks post oxygen therapy.  Who clinically significant improvement on breathlessness at baseline and 1 or two weeks post oxygen therapy.  Who clinically significant improvement on breathlessness at baseline and 1 or two weeks post oxygen earlier in disease trajectory did have clinically significant improvement in breathlessness which may be related to exertional dyspnoea.	Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
Adult patients with cancer and other life limiting lillness prescribed oxygen. Patient rated symptom assessment scale for each clinical contact in the community but could not include pulse oximetry.  Smith J Abernathy A 2009 Palliative med 23;309  Adult patients with cancer and other life limiting lillness with cancer and other life limiting lillness in prescribed oxygen. Patient rated symptom assessment scale as 2 weeks pre initiation of oxygen and 2 weeks post oxygen and 2 weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen oxygen therapy.  Who the stated symptom assessment scale as 2 weeks pre initiation of oxygen and 2 weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for or breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for or breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for or breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale for or breathlessness at baseline and 1 or two weeks post oxygen therapy.  Symptom assessment scale as 2 weeks pre initiation of 5 oxygen and 2 weeks post oxygen therapy.  Symptom assessment scale as 2 weeks pre initiation of 5 oxygen and 2 weeks post oxygen therapy.  Symptom assessment scale as 2 weeks pre initiation		type	level		characteristic				measures		
Smith J Abernathy A 2009 Palliative med 23;309 with cancer and other life limiting illness prescribed oxygen. Patient rated symptom assessment scale as 2 myetor assessment scale as 2 weeks pre inititation of oxygen and 2 weeks post oxygen therapy.  I or two weeks pre inititation of oxygen. One third patients who were prescribed oxygen earlier in disease trajectory did have clinically significant improvement in breathlessness which may be related to exertional					S						
	Smith J Abernathy A 2009		2-	5862	with cancer and other life limiting illness prescribed oxygen. Patient rated symptom assessment scale for each clinical contact in the community but could not include	therapy via concentrator for relief of symptomatic breathlessnes s following referral to palliative care.	assessment scale as 2 weeks pre initiation of oxygen and 2 weeks post		assessment scale for breathlessness at baseline and 1 or two weeks post oxygen	significant improvement on breathlessness demonstrated despite introduction of oxygen. One third patients who were prescribed oxygen earlier in disease trajectory did have clinically significant improvement in breathlessness which may be related to exertional	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
111 Short burst oxygen therapy after activities of daily living in the home in chronic obstructive pulmonary disease. Quantrill, S. J.; White, R.; Crawford, A.; Barry, J. S.; Batra, S.; Whyte, P.; Roberts, C. M. Thorax 2007;62:702-705.	double blind RCT crossover study	1+		14M/8F, age 72(7.3)56-86, FEV1 0.87(0.38)0.40- 1.69. FEV1%pred 38.0(16.1)17-74. SaO2 % resting RA 93.1(3.8) 82- 98%. Desaturation with activity 7.5(- 2.5 to 0.5)%. Patients were currently using O2 for activities	4 patients and Cylinder Compressed air via nasal cannulae post activity	4l/min post activity versus compressed cylinder air post activity		subjective(pts percieved recovery) and objective (SaO2 returned to within 2% and HR to within 5 bpm of pre activity values). Recovery post activity. Breathlessness was measured with VAS.	Median ( mean)of activities1 and 2 objective O2 75(97)s, RA 110 (135)s, p=0.08. Subjective O2 186(186)s, RA 240(219)s p=0.06.	amenity fund

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
112 study 1. Oxygen supplementation before or after submaximal exercise in patients with chronic obstructive oulmonary disease.  Nandi, K.; Smith, A. A.; Crawford, A.; MacRae, K. D.; Garrod, R.; Seed, W. A.; Roberts, C. M. Thorax 2003;58:670-673.		1+	34	Stable COPD, age 68(5.98), FEV% pred 34(13.1), PaO2 kPa RA 7.7(13.1)(5.14- 10.50), SaO2 RA resting 91.9(5.2)(76-97). Walk distance RA (m) 283(117.8)(70- 490).	28% mask versus cylinder air for 10 minutes	O24I/min via 28% mask versus cylinder air for 10 minutes pre exercise		oxygen saturations(SaO 2), breathleasness( VAS), and recovery time- subjective(SRT) and objective(ORT).	6MWT O2 288(20.8), Air 283(20.3) mean diference 5. Fall in SaO2-O2 11.0(1.1), air 9.4(1.1) mean dif(1.6)(p=0.01). Change in VAS from baseline O2 58(4.3)mm, air 54(3.8)mm. SRT(s) 111(19.6), air 142(16.5) mean dif 13. ORTO2 177(20.6), air 184(31.7)mean dif 7. SBOT for 5 minutes pre exercise did not improve breathlessness, exercise capacity or reduce recovery time.	non declared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
supplementation before or after submaximal exercise in patients with chronic obstructive pulmonary disease. Nandi, K.; Smith, A. A.; Crawford, A.; MacRae, K. D.; Garrod, R.; Seed, W. A.; Roberts, C. M. Thorax 2003;58:670-673.	RCT	1+	18	Stable COPD patients age 68(6.87), FEV1%pred 29(6.1)(19-40). PaO2 kPa RA 7.68(1.37). SaO2 resting RA 90.5(5.8). 6MWT 233(88.6).	or cylinder air for 5 minutes immediately after 6MWT	Cylinder oxygen 4l/min via 28% mask or cylinder air for 5 minutes immediately after6MWT		Saturations% (SaO2) at 5 mins. VAS(mm) at 5 mins, subjective recovery time SRT, Objective recovery time ORT.	SaO2 at 5 min O2 92.7(1.1), air 89.9(1.2) mean dif 2.7, p<0.0001. VAS 5 mins O2 14(3.6), air 19(5.7) mean dif 5. SRT O2 182(33.1) air 151(17.7) mean dif 31. ORT O2 215(38.4) air 164(17.9) mean dif 51. SBOT for 5 minutes post exercise does not significantly	non declared
113 Short burst oxygen immediately before and after exercise is ineffective in nonhypoxic COPD patients. Lewis, C. A.; Eaton, T. E.; Young, P.; Kolbe, J. Eur Respir J 2003	RCT	1+	22	stable COPD, age 68.7±10.1(47- 82). FEV%pred 34.0±12.0(19- 59). Resting SaO2% 94.4±1.6(92-98)	oxygen(O2) 2L/min versus cylinder air 2L/min	O2 2 Lmin nasal cannulae versus cylinder air 2L min pre and post exercise		The effect of SBOT on performance when administered before and after exercise.	before exercise 6 MWT Visit 1- air 373.5±18.3, O2- 383.6±17.7. V2 air-388.2±20.5, O2 390.3±18.7. After execise finaL Borg 4.8±0.4, O2 5.1±0.4, V2- air 5.1±0.5, O2 4.9±0.4 0. recovery after exercise seconds- V1 air 166.5+12.0, O2 168.6±12.2, V2 air 160.0±15.7, O2 141.7±12.6	non declared

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
•	type	level	-	characteristic		•	_	measures		
				s						
114 B Ronan O'Driscoll, Jane Neill, Siddiq Pulakal and Peter M Turkington. A crossover study of short burst oxygen therapy (SBOT) for the relief ofexercise induced breathlessness in severe COPD. BMC Pulm Med. 2011;11:23	RCT	1++	34		O2, room air, compressed air and fan.	O24L/min from face mask(OM) versus room air from face mask(RA), compressed air(AM) and air from electric fan(EF)	1 day	reduction of dyspnoea post exercise. Difference in dyspnoea and time to recover between O2 room air, compressed air and air from fan.	RA 93.7(42.1), EF 92.9(43.2), AM94.1(40.5), OM93.0(46.1), pulse end of exercise- RA 99.3(18.6), EF 103.6(16.6), AM 107.0(19.7), OM 102.1(16.2). SpO2- RA 91.3(4.0), EF 91.1(3.7), AM 91.5(3.5). End exercise Borg-5.1(1.7), EF 5.1(1.7), AM	Salford Respiratory Fun
									5.3(1.6), OM 5.1(1.7). Subjective recovery(SR) mins- RA 3.2(1.1), EF 3.6(1.8), AM 3.3(1.1), OM 3.1(1.2), objective recovery(OR)- RA 2.8(2.0), EF 2.3(1.1) AM 2.9(2.5) OM 1.9(1.0), 14 pts	
									who desaturated SR- RA 3.2(1.1), EF 3.4(1.1), AM	

Bibliographic citation	Study type	level	•	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
15 Short burst oxygen herapy for relief of breathlessness in chronic obstructive airways disease. Evans T. W.; Waterhouse, J. C.; Carter, A.; Nicholl, J. F.; Howard, P. Thorax 1986;41:611-615		1+		with shortness of breath as principle complaint, 16M/3F, mean	versus placebo via facemask	Time in recovery following exercise as measured by change in VAS, RR, HR.		recovery time following exercise as measured by VAS, RR, HR. Reproducibility of measurements over time	Recovery time for HR- Placebo- 3.76(SD3.02), RA 3.42(1.16), O2 3.31(1.78)(p>0.05)). RR-placebo 4.21(2.79), RA 4.39(2.51), O2 3.66(2.01), (p>0.05). VAS 3.63(1.33), RA 3.55(0.94), 3.03(1.11). Plasebo v RA p=1.0, placebo v O2 p=0.046, RA v O2p= 0.046.	

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
• .	type	level	•	characteristic		-		measures		
				s						
	RCT	2++	18	12M, 6F. Age	cylinder	The effect of		Resting Borg		none declare
PMA CalverleyEffect of				61.2(4.4), FEV1					mouthpiece(AM),	
oxygen on recovery					cylinder air	cylinder		B) and leg score		
rom maximal exercise				(%pred )		oxygen(0.4)		(BL), exercise	mouthpiece(O2M)	
n patients with chronic				40.28(15.93), IC		10Lmin via		duration,	0.75(0.25), air	
obstructive pulmonary				2.17(0.64),		venturi mask		maximal	mask 1.03(0.26),	
disease. Thorax				IC%pred86.88(2		post exercise.		exercise Borg	O2 mask	
2004;59:668-672				5.27)					0.74(0.21). BL-	
2004,39.000-072				MIP(cmH2O)				maximal Borg	(AM) 1.06(0.31),	
				70.18(16.47), MEP				leg score,	(O2M) 1.03(0.25),	
				—.				Maximal	air mask	
				105.28(21.98) SaO295.9(1.66),				workload(W), VO2 max(l/min),	0.94(0.27), O2 mask 0.97(0.26).	
				resting BORG				VCO2	Exercise	
				0.84(0.87),				max(I/min)	time(min)-	
				resting Borg leg				max(i/min)	(AM)8.16((0.96),	
				score 1.0(1.12).					(O2M) 7.07(0.87),	
				30016 1.0(1.12).					air mask	
									8.18(0.95), O2	
									mask 8.65(0.98).	
									Max ex Borg-AM	
									5.36(0.55), O2M	
									5.17(0.51), air	
									mask 5.26(0.49),	
									O2 mask	
									5.41(0.51). Max	
									ex Borg leg- AM	
									5.56(0.47), O2M	
									5.19(0.39), air	
									mask 5.00(0.50),	
									O2 mask	
									5.44(0.52). W -	
									AM 37.22(5.53),	
									O2M 32.78(5.47),	
									air mask	
									29 22/E 20\ O2	

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic		_	_	measures		
				s						
17 Short burst oxygen herapy for COPD patients; a 6 month andomised controlled study. Eaton, T.; Fergusson, W.; Kolbe, I.; Lewis, C. A.; West, T. European Respiratory Journal April 1st, 2006 vol 27 no. 4697-704.	RCT	1++	78, 25 cylinder O2(O2), 26 cylinder air(A), 27 usual care(27).			cylinder O2 2L/min via nasal cannulae PRN, versus cylinder air 2l/min PRN, versus usual care.		change in health related quality of life, acute healthcare utilisation measured with CRQ, SF-36 HAD over 6 months study period.	82.9±21.8, A- 77.0±16.3, UC- 73.3±14.3. SF36 mental O2- 30.4±8.9, A-	Aukland Medica Research Foundation, Green Lane Hospital Research and Educational Fund.

Bibliographic citation	Study type	Evidence level	•	characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
118 Cohen, A. S.; Burns, B.; Goadsby, P.J. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA: the journal of the American Medical Association, 2009. Vol. 302, 22 2451-7		1++		Adults (aged 18-70 yrs) with cluster headache as defied by the international Headache society		High flow oxygen Vs placebo		Secondary aims were pain free at 30 min, reduction in pain scales at 15, 30, 45 and 60 min,	episodic 19 with chronic cluster headache were available for analysis. The difference between Oxygen, 78% for 150 attacks and air 20% for 148 attacks was significant. There was no important	Univ College of London and BOC Ltd who supplied the cylinders and masks.

Study		•	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
type	level		characteristic				measures		
			S						
two separate studies published in one paper. First one cohort study. 2nd Cross over trial	2		Adult patients	In First study, 100% oxygen through face mask at a rate of 7L/min for 15 minutes.In 2nd study, crossover trial with sublingual ergotamine and oxygen.		patient treated	in 7 of 10 attacks	pain in 75% of	Not stated
Double blind cross over study	2	19	men aged 20-50 years	Oxygen vs air inhalation at 6 L/min via nonrebreathing face mask for 15 minutes for up to six headaches.	oxygen vs air	for upto 6 episodes of headaches	reporting of pain relief as none, slight, substantial	the average relief score for Oxygen treated patients was 1.93 and for air 0.77 out of a possible score of 3	
						r			
case reports	3	3	2 Adult smokers with chronic cluster headache. 1 adult non smoker with episodic cluster headache.	Higher flow rate oxygen at 14-15 L/min	standard oxygen therapy at rate of 7 to 10 L/min compared with high flow rate of 15L/min		headache relief	all 3 patients responded to high flow oxygen when standard flow oxygen had failed.	Not stated
	type  two separate studies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over study	two 2 separate studies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over	two separate studies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over study  2 52 in first study, 50 in 2nd study  Double blind cross over study  19	two separate studies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over study  case reports  3  2 52 in first study, 50 in 2nd with active episodic or chronic cluster headaches.  Pouble blind cross over study  2 19 men aged 20-50 years  3 2 Adult smokers with chronic cluster headache. 1 adult non smoker with episodic cluster	two separate study. 50 in 2nd study	two separate study. 50 in 2nd study policy of the properties of suddies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over study  Case reports  3  3 2 Adult smokers with chronic cluster in adult non smoker with episodic cluster in adult non smoker with episodic cluster in adult non smoker with episodic cluster in a dult non smoker with episodic cluster in adult non smoker with episodic cluster in a dult non smoker with episodic cluster of 7t./min for 15 minutes. In 2nd study, crossover trial with chronic cluster in halation at 6 L/min via nonrebreathing face mask for 15 minutes for up to six headaches.  Higher flow rate of 7to 10 L/min compared with high flow rate of 15L/min in compared with high flow rate of 15L/min in properties in 22 minutes for up to 15L/min compared with high flow rate of 15L/min in compared with high flow rate of 15L/min in properties in 22 minutes for up to 15L/min compared with high flow rate of 15L/min in compared with in compared with in compared with high flow rate of 15L/min in compared with in com	two separate studies published in one paper. First one cohort study. 2nd Cross over trial  Double blind cross over study  Trial  Double blind cross over study  Double blind cross over trial  Double blind cross over study  Trial  Double blind cross over trial  Dovigen vs air  Dou	two separate study. So in 2nd study sudy study study and patients study. So in 2nd study study. So in 2nd study study and patients study. So in 2nd study study study. So in 2nd study study and patients study. So in 2nd study study. So in 2nd study study. So in 2nd study study. So in 2nd study. Substantial or 2nd study. So in 2nd study. So in 2nd study. So in 2nd study. Substantial or 2nd study. So in 2nd study. So in 2nd study. So in 2nd study. Substantial or 2nd study. So in 2nd study. So in 2nd study. Substantial or 2nd study. So in 2nd study. Substantial or 2nd study. So in 2nd study. Substantial or 2nd study. Su	two separate study sudy sudy study s

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
				s						
122 Backx, A. P. M.; Haane, D. Y. P.; De Ceuster, L.; Koehler, P. J. Cluster headache and oxygen: is it possible to predict which patients will be relieved? A retrospective cross- sectional correlation study. Journal of Neurology, 2010. Vol 257, 9 1533-42		2+		patients from headache clinic or those who responded to website call for study. Patients with cluster headache who had used Oxygen <10 yrs pre study, duration of headache upto 24 hrs	oxygen therapy	none	questionnaire study	study was to provide a clinical predictive model for oxygen	patients who smoked in the past, had shorter attacks and were pain free interictally respond better to Oxygen inhalation.	not stated

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
124 Johns DP;Rochford PD;Streeton JA; Evaluation of six oxygen concentrators 1985 Thorax 806 - 10 Oxygen concentrators 1993 Health devices 485-97	lt .	2+	N/A	6 devices	None	6 oxygen concentrators		28 day period to determine (1) the oxygen yield (%O2) over the flow range 1-4 I min-1; (2) 90% oxygen rise time (90% RT) from a cold start when they were operated at 2 I min-1; (3) accuracy and readability of the flow device; (4) static outlet pressure; (5) major components comprising the product gas (Hudson only); and (6) general characteristics. At an outlet flow of 2 I min-1 the mean % O2 generated by	than plus-or- minus sign 0.5%. The Dom 10, Econo 2, and Hudson consistently	Not stated

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
125 Hall LW;Kellagher REB;Fleet KJ; A portable oxygen generator 1986 Anaesthesia 516 - 8	Technical report	3	N/A	N/A	N/A	N/A		The use of a portable generator which liberates oxygen from hydrogen peroxide solutions has been investigated in veterinary anaesthesia to assess its potential as an alternative to conventional oxygen supplies both in emergency situations and in the event of failure of cylinder systems. The reliability of the supply appears to be good and the operation of the generator simple, making it suitable for a		Not stated

	type	level	•	Patient characteristic	Comparison	Length of f/u	measures	Effect size	Funding
126 Gould GA;Scott W;Hayhurst MD;Flenley DC; Technical and clinical assessment of oxygen concentrators 1985 Thorax 811 - 6	Equipmen t comparis on	2+		s 12M:8F, 47-93 years, Type 2 Respiratory Failure on HOS. 4 Devices compared	O2 concentrator vs Air		One membrane oxygen enricher (Oxygen Enrichment Company OE- 4E) and four molecular sieve (MS) concentrators (Mountain Medical Econo2, De Vilbiss MINI DeVO2, Cryogenic Roomate III, and Mountain Medical Mini O2) have been studied to assess technical and clinical performance. During four weeks of continuous operation at a flow rate of 2 I min-1 (6 I min-	SpO2 increased on average from 83% to 93%	Not stated

Bibliographic citation	Study		No patients	Patient	Intervention	Comparison	Length of f/u		Effect size	Funding
	type	level		characteristic				measures		
128 Burioka N;Takano K;Hoshino E;Suyama H;Saito S;Sasaki T; Clinical utility of a newly developed pressure swing adsorption-type oxygen concentrator with a membrane humidifier 1997 Respiration 268 -72	Equipmen t compario sn	3	13	Receiving LTOT	Air vs oxygen	Concentrators with differenr technologies		The clinical utility of the newly developed pressure swing adsorption (PSA)-type oxygen concentrator with a membrane humidifier that does not require added water for humidification was evaluated in 13 patients with chronic pulmonary disease who were receiving long-term oxygen therapy. PaO2 and the relative humidity were measured when the patient breathed air and oxygen	A significant difference was observed between the relative humidity of room air (44.7 +/- 18.6%) and that of the oxygen flow (72.7 +/- 14.8%) from the new device. None of the patients experienced dry nasal passages, dry throat, or any other adverse effects. Since this new PSA-type oxygen concentrator with a membrane humidifier supplies well-	Not stated

Bibliographic citation	Study type	Evidence level	•	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
129 Burioka N;Takano K;Suyama H;Chikumi H;Hoshino E;Sasaki T; Efficacy of newly developed pressure swing adsorption type oxygen concentrator with membrane humidifier: comparison with conventional oxygen concentrator with bubble water humidifier 1997 Internal medicine (Tokyo Japan). 861 -4	Equipmen t compario sn	3	10	COPD	Air vs oxygen	concentrator with membrane hunmidifier and one without	Single case	To examine the clinical efficacy of a newly developed pressure swing adsorption (PSA) type oxygen concentrator with a membrane humidifier	answered that there was no difference on subjective impression between breathing oxygen from the new machine and from the conventional oxygen concentrator. Sufficient relative humidity (above 50%) of oxygen flow was obtained by using	Not stated

	ype		-1		Comparison	Length of f/u		Effect size	Funding
130 Pesce LI;Bassi R		level	characteristic s				measures		
GN;Santovito A; Clinical usefulness of a new portable oxygen concentrator Clinical usefulness of a new portable oxygen concentrator 1994 Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro IRCCS (and) Istituto di clinica tisiologica e malattie apparato respiratorio Universita di Napoli Secondo ateneo Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro IRCCS (and) Istituto di clinica tisiologica e malattie del torace / Fondazione clinica del lavoro IRCCS (and) Istituto di clinica tisiologica e malattie apparato respiratorio Universita di Napoli Secondo ateneo 444 -446	RCT	2++	s Hypoxaemic	Air vs oxygen	Air vs O2 concentrator vs o2 concentrator with demand valve			No difference	Not stated

	type	level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
131 Shiner RJ;Zaretsky U;Mirali M;Benzaray S;Elad D; Evaluation of domiciliary long-term oxygen therapy with oxygen concentrators 1997 Israel journal of medical sciences 23 - 9	Equipmen t evaluatio n		2414 machines	Patient on oxygen	Oxygen concentrator s	N/A		In France, 12,000 patients receive long- term oxygen therapy at home supplied by oxygen concentrators (OCs) which are provided by a non- profit organization, the National Home Treatment for Respiratory Insufficiency Association (ANTADIR31 regional associations). OCs are regularly checked at home by technicians from the associations. Technical data, oxygen fraction (Fo2) supplied at working flow-		N/A
	l								ĺ	I

Bibliographic citation	Study type	level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	measures	Effect size	Funding
M;Shneerson J; An evaluation of the use of concentrators for domiciliary oxygen supply for less than 8 h day-1 1998 Respiratory medicine 250 -5	RCT	2++	26	On home oxygen	Oxygen concentrator s			Since their introduction in 1985, oxygen concentrators have only been recommended when domiciliary oxygen is used for over 8 h day-1. Subsequent changes in the prices of oxygen merit a reappraisal of the prescribing of concentrators and cylinders when oxygen is used for less than 8 h day-1. Twenty-six patients in two health districts who used oxygen for less than 8 h day-1 completed a crossover study in which		N/A

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	-	characteristic		-		measures		
				s						
133 Cuvelier, A.; Nuir, J. F.; Chakroun, N.; Aboab, J.; Onea, G.; Benhamou, D.: Refillable oxygen cylinders may be an alternative for ambulatory oxygen therapy in COPD: Chest 2002:451-6	RCT	-	10	Stable COPD patients already established on O2 who could undertake a wlk test	Randomised cross-over trial single blind looking at whether Self-fill system (portable cylinder filled from a concentrator) are equivalent to standard ambulatory cylinders on a 6 minute walking tests.	Self-fill portable system compared with standard ambulatory		Outcome of 6 minute walk test SaO2 and cardiac frequency plus Borg dyspnoea score	difference between the 2 despite the Self- fill having a lower fill	N/A

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
134 Strickland, S. L.; Hogan, T. M.; Hogan, R. G.; Sohal, H. S.; McKenzie, W. N.; Petroski, G. F.: 2009	Controlled	+	39 (44% could notcomplete walking test)	Stable COPD patients (grade IV GOLD very severe obstruction) resting sPO2 on air < 90%. All prescribed LTOT + ambulatory with cylinder, shoulder bag and nasal cannulae.	*	liquid, Self-fill cylinder, portable concentrator, ambulatory cylinder): All were pulsed flow		Patients undertook a 6 minute walk test on each piece of equipment, sPO2 , walk time and distance was recorded after each test and the patients opinion of the equipment used	difference between the sPO2. distance	Sponsored by Puritan Bennett Home Care

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
				s						
135 Lock, S. H.; Blower,	RCT	+	15	13 COPD 1ILD		Liquid O2	16 weeks	Outcome	There was no	Puritan-Bennet
G.; Prynne, M.;				, , , , , , , , , , , , , , , , , , ,	O2 on	compared		measures	significant	and Air
Wedzicha, J. A.:				requiring	ambulation	with cylinder		were distance	change in	Products Ltd
Comparison of liquid				ambulatory O2	· ·	O2 for		walked, VAS	walking distance	
·					with cylinder	ambulation		dyspnoea —	after eight	the equipment
and gaseous oxygen for					O2 to see if			score, The	weeks of	and liquid
domiciliary portable					increase in			chronic	gaseous	
use: 1992 Thorax; 98-					walking			respiratory	oxygen. There	
100					distance and			disease index	were no	
					improved			•	significant	
					quality of life.			They also kept		
					Walking			a diary card at		
					tests at the			home	values or arterial	
					start of the			throughout the	~	
					study then			, ,	tensions at any	
					after 8 weeks				time during the	
					of home use			hours they	study.	
					on one				Information from	
					modality then			(a) using the	diary cards was	
					8 weeks of			portable	available for	
					home use on the other			systems, (b)	only 13 patients.	
								out of doors,	The patients	
					modality			and (c) using	used the liquid	
								their oxygen concentratorsl	oxygen for	
									significantly longer (median	
								mpovement in distance	23 5 hours a	
								walked and	week) than the	
								quality of life (VAS score).	gas cylinder (10 hours a week,	
								shows that	95% CI 4-2 to	
								liquid O2 is	23 3 hourssee	
								liquiu UZ 18	23 3 HOUISSEE	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
136 Nasilowski, J.; Przybylowski, T.; Zielinski, J.; Chazan, R. 2008 Resp Med	RCT	++	13 completed	Severe COPD patient on LTOT	walking testt to see if	Comparing Liquid O2 with continuous flow and portable concentrator with pulsed flow for ambulation		saburi	higher oxygen purity (mean <sub>i</sub> SD % oxygen concentration) at 1 L?min-1 than at 5 L?min-1 (94.4 <sub>i</sub> 0.5 versus 85.8 <sub>i</sub> 0.8, p=0.03). Comparatively, wall oxygen had a consistently high concentration (99.6 <sub>i</sub> 0.5 at 1	

	type	level		characteristic		Comparison	measures		
137 Andersson, A.; Strom, K.; Brodin, H.; Alton, M.; Boman, G.; lakobsson, P.; Lindberg, A.; Uddenfeldt, M.; Walter, H.; Levin, L. A.: Long-term oxygen cherapy using portable oxygen devices: pulsed oxygen-delivery via demand system at rest and during exercise: 1998: European Respiratory Journal. 1284-1289	RCT	+	based on 47 patients)	patients (all but 4 were COPD) with pulmonary disease that could use and were willing to use portable equipment outside the	by the	compared	and QOL. Patient diary of health professional contacts (to	Mr Dunne presented a version of this paper at the symposium COPD: Empowering Respiratory Therapists to Make a Difference, at the 54th International Respiratory Congress of the American Association for Respiratory	

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
				S						
138 Katsenos, S.;	Observati	+	104	Stable COPD			6 month trial		23 5 hours a	
Charisis, A.;	onal study			patients on		compared		looking at	week) than the	
Daskalopoulos, G.;	·			home oxygen		with liquid		compliance and	gas cylinder(10	
Constantopoulos, S. H.;				(> 3months)		oxygen during		opinion about	hours a week,	
Vassiliou, M. P. Long-						daily living		equipment.	95% CI 4-2 to	
term oxygen therapy in					improved compliance				23 3 hourssee fig 1). When	
					and quality of				using gaseous	
chronic obstructive					life of LTOT				oxygen patients	
pulmonary disease: the					patient. Not				went out of the	
use of concentrators					cross over				house on	
and liquid oxygen in					study				average 15-5	
North Western									hours a week,	
Greececoncentrators									whereas with	
									liquid oxygen	
									they went out 19	
									5 hours a week	
									(fig 2), a small	
									but When they	
									had a gas	
									cylinder patients	
									spent a median of 114 hours a	
									week using their	
									oxygen	
									concentrator,	
									whereas with	
									liquid oxygen	
									they	
									_	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
	· ypc	10 401		S				incusui cs		
139 Czajkowska-	Prospecti	+	30	Patients on		Liquid oxygen	? 6 months	6 min walk,		N/A
Malinowska, M. P.,	ve study			LTOT with		with static		MRC score,		
B.:Ciesielska, A.:Kruza,				chronic		concentrator		QOL score,		
K.:Jesionka, P.				respiratory				activity scores (Borg, Katz,		
Comparison of the				insufficiency				Lawton, BTS).		
results of long term								Spirometry,		
oxygen therapy in								Blood gases.		
patients treated										
sequentially using										
stationary or a portable										
source of										
oxygen:Porownanie										
wynikow domowego										
leczenia tlenem u										
chorych leczonych										
sekwencyjnie za										
pomoca{ogonek}										
stacjonarnego i										
przenosnego zrodla										
tlenu. 2012.										
Pneumonologia i										
Alergologia Polska.308-										
316										

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
14 Paul, J.; Otvos, T.: 2006. Comparison of nasal cannulas and the OxyArm in patients requiring chronic domiciliary oxygen therapy: Canadian respiratory journal: journal of the The European respiratory journal: 778-81	RCT	+	25	Adults already receiving home oxygen for severe COPD (stable)	comparing the oxy-arm with nasal cannulae on walkingtests and 4 week home trial			at flows of 2, 3, 4, 5, 6, 7 I/min after 10 mins 5 satn were measured 10secs apart and the mean calculated. 2 walk tests were then performed on the 2 devices and distance walked and satn (as previously measured) was measured at the	(OA) proved to be similar to Nasal cannulae (NC's) in delivering oxygen and maintaining saturation in patients on LTOT. After the 4	Grant from Southmedic inc. Canada

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic s	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
143 Domingo C;Roig J;Coll R;Klamburg J;Izquierdo J;Ruiz MJ;Morera J;Domingo E; Evaluation of the use of three different devices for nocturnal oxygen therapy in COPD patients 1996 Respiration 230 - 5	RCT	3	14	Hypoxaemic	Oxygen via na	Nasal cannulae or oxymizer		OBJECTIVE: To determine whether transtracheal catheter and reservoir nasal cannula contribute to maintaining adequate oxygen saturation during sleep, and to calculate the oxygen saving they allow compared to nasal prongs. DESIGN: A prospective study in which patients were randomly	N/A	Not stated

142 Moore GJC;George RCT 2++ 12 Hypoxaemic Air vs nasal ca Standard nasal cannula 1985 Thorax 817 - 9	ū	Oxygen administration via a nasal cannula incorporating a small collapsible reservoir (Oxymizer, Chad	8/12 patients in	nproved. Oxy
		Therapeutics Inc, California) was compared with delivery via a standard nasal cannula. Twelve patients with chronic, stable hypoxaemia (arterial oxygen tension less than 60 mm Hg (8.0 kPa)) were studied. Transcutaneou s oxygen and carbon dioxide tensions were recorded by		

145 Roberts, C. M.; Bell, J.; Wedzicha, J. A. Copp patients with severe desaturation on exercise oxygen delivery system with continuous low flow oxygen in subjects with stable Copp and  The patients are destronic conserver versus continuous flow at 2L/min flow oxygen at a standard stable Copp and  The patients are destronic conserver versus continuous flow oxygen at a standard flow oxygen at a standard stable Copp and  The patients are destronic conserver versus continuous flow oxygen at a standard flow oxygen at a standard flow oxygen at a standard flow oxygen use	Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
patients with severe desaturation. Patients need to be assessed on the conserver if this is to be prescribed	Bell, J.; Wedzicha, J. A. Comparison of the efficacy of a demand oxygen delivery system with continuous low flow oxygen in subjects with stable COPD and severe oxygen desaturation on walking 1996 Thorax 51		++	15	with severe desaturation	conserver versus continuous flow at 2L/min (equiv) on	conserver versus continuous flow oxygen at a standard		rate, visual analogue breathlessness score and SaO2. walking distance, subjective time to recovery, objective time to recovery, lowest recorded satn, time spent with satn <	going to use O2 outside of the home and need greater mobile oxygen use patients should be tested on a conserver before prescribing. Using a conserver with cylinder oxygen was poor for correcting desaturation on exercise compared with continuous oxygen in COPD patients with severe desaturation. Patients need to be assessed on the conserver if this is to be	Life Support (Europe) for the loan of the oxymatic devices used during the study Oxymati devices used i the study.

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level		characteristic				measures		
146 SR Braun, G Spratt, GC Scott and M Ellersieck. Comparison of six oxygen delivery systems for COPD patients at rest and during exercise. 1992: Chest; 694 - 698	RCT	1+	10	Patients with severe COPD as per the NOTT study	To see if oxuygen conserving devices gave adequate oxygenation at rest and during exercise compared with continuous flow	5 different conserving devices (with different modes of delivery) were compared with each other and with continuous flow at rest and on exercise. Flow on exercise set to physician prescribed O2.		min walk test and pulse rate and Sao2 recorded from	showed a significant desaturation on exercise whatever device was used including continuous flow. The conservers	N/A
147 Marti s, Pajares V, Morante F, Ramon M- A, Lara J, Ferrer J, Gwell M-R. Are oxygen conserving devices	Open cross sectional cross-over study	2+	59	COPD and ILD with exercise desaturation	exercise test to see if conservers are acceptable	DOD, oxygen pendant to standard continuous flow		6 minute walk (desat, Borg, HR, BF)	N/A	N/A

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
• .	type	level	-	characteristic		-		measures		
				s						
148 Chatburn, R. L.; Lewarski, J. S.; McCoy, R. W.: Nocturnal oxygenation using a pulsed-dose oxygen- conserving device compared to continuous flow: Respiratory Care: 2006	RCT	-	10	Patients had either emphysema or pumonary fibrosis with a history of prolonged oxygen use	sleep study to rule out sleep apnoea and to	O2 compared with pulsed using Inogen with 2 different settings sesitive and normal.		Overnight saturation comparison on the different modalities. Sho wed a significant statistical difference in O2 level but authors felt this was not a clinical difference. One patient did have a clinically significant	oxygenated during sleep while using the RNC	N/A

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
149 Andres, D. Randomized double- blind trial of the effects of humidified compared with nonhumidified low flow oxygen therapy on the symptoms of patients: 1997: Canadian Respiratory Journal; 76-80	RCT	++	157 medical and 87 surgical patients	patients admitted to hospital requiring oxygen.	flow oxygen (4L/min or less)	Humidified low flow O2 with non-humidified low flow. Symptoms and problem score	maximum of 6 days	symptom questionnaire. The primary symptom of interest was dryness secondary nosebleeds. They showed there was no difference in symptoms on questionnaire in patient on humidified low flow O2 (< 4L/min) compared with non-humidified. Did show whichever arm the patient was on that they improved with time.		Alberta lung association ans foothills hospita research and development committee

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
152 Pendleton N, Cheesbrough JS, Walshaw MJ, Hind CRK Bacterial colonisation of humidifier attachments on oxygen concentrators brescribed for long term oxygen therapy: a district review. Thorax. 16, 257-258		3	8	Patients with severe chronic airflow obstructionusing bubble through humidification with their home oxygen concentrator	with samples taken from the humidifiers after water change, taken	Cultured organisms compared from each patient, their humidifier and water supply		Number (colony forming units/ml) and range of organisms cultured from humidifiers		Undisclosed

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding	
	type	level		characteristic				measures			
				s					-		
153 Leggett, R. J.;	RCT	+	19	19 chronic	The effects of the way	Walking test	N/A	Minute	system, the	RJELeggett	
Flenley, D. C.: Portable				hypoxic cor	portable	on air and O2		ventilation, O2	Union Carbide Oxygen Walker,	was supported	
oxygen and exercise				pulmonale	oxygen is	plus carrying		uptake, CO2	althoug1o	by the MRC	
tolerance in patients				patient with		a ambulatory		output, pH,	convenient and		
with chronic hypoxic				pulmoonary	ambulation (also	cylinder		PaO2, PaCO2	practicable,		
cor pulmonale				hypertension	physiology in	compared		and distance	does carry the		
1977: BRITISH MEDICAL				as a result of	this paper)	with a trolley.		walked but	disadvantage		
JOURNAL: 84-6				COPD		NB Three		also a lot of	that the		
						subgroups		physiology in	extra weight of the equipment		
					were		this paper	hinders the			
				studied, some			patient's				
					patients being			performance.			
						common to			We suggest that		
						each group:			wheeling the		
						group 1				oxygen walker	
								included			on a simple, cheap,,
						eight patients			lightweight		
						who walked			trolley will allow		
						when			these breathless		
					breathing air			patients to			
						or 2 1 of			derive		
						oxygen/min			benefit from		
						with and			oxygen during exercise, in		
						without the			addition to the		
									undoubted		
						oxygen			benefit that they		
						walker. Group			already obtain		
		ĺ				2 comprised			from having a		

Bibliographic citation	Study	Evidence	No patients	Patient	Intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	-	characteristic		-		measures		
	,,			s						
154 Crisafulli, E.; Costi, S.;	RCT	+	60	Patients	The effects of	Wheeled cart	N/A	Walking speed,	A simple change	NK
De, Blasio F.; Biscione,				established on	the way	and portable		leg fatigue and	in the way	
G.; Americi, F.; Penza, S.;				LTOT (COPD as		cylinder			ambulatory O2 is	
Eutropio, E.; Pasqua, F.;				per GOLD	oxygen is	compared with		were th primary	carried may make	
Fabbri, L. M.; Clini, E. M.				guidelines)	transported on	back pack and			a significant	
2007: Effects of a walking						cylinder		measures with	change on QOL.	
aid in COPD patients									Moreover,	
eceiving oxygen therapy:								being the	cardiorespiratory	
Chest: 1068-74								secondary	parameters	
								measures	recorded during	
									the walking	
									activity	
									(secondary	
									outcomes) were	
									significantly better	
									with the cart as	
									was the walking	
									speed. The same	
									improvements in	
									both primary and	
									secondary	
									outcomes due to	
									the cart were	
									even more	
									striking in the	
									subgroup of	
									patients who had	
									a walking	
									distance < 300 m,	
									whereas no	
									significant	
									differences were	
									observed in the	
									subgroup	
									of patients who	

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
associated with smoking during long-term oxygen therapy-Maine, Massachusetts, New Hampshire, and Oklahoma, 2000-2007. MMWR morbidity and mortality weekly report2008; Vol57/No31: 852-854	case study	3		38 cases, age 9-87 24(63%) female 37 lived in private residence, I lived in nursing home		Fatalities associated with home oxygen use		by smoking andhome oxygen use	38 cases, 34(89%) on LTOT and smoking, 3(8%) household members of LTOT smokers, 1(3%) non smoker on LTOT ignited by smoker who lived in house. 22(58%) died on day of fire, 7(18%) died next day 9(24%) survived med 15 (3-41)dys	none declared

Bibliographic citation	Study	Evidence	No patients	Patient	intervention	Comparison	Length of f/u	Outcome	Effect size	Funding
	type	level	-	characteristic		-	_	measures		
				s						
156 Home oxygen therapy;Adjunct or risk factor. Robb, Bruce W.; Hungness, Eric S.; Hershko, Dan D.; Warden, Glenn D.; Kagan, Richard J. Journal of Burn Care and Rehabliation. 2003;24:403-406		3		27 patients with burns attributed to oxygen. 14M/13F,age 68(40-82). 25(93%) had COPD. 3 lived in nursing home and 1 was an inpt in acute care	burns	burns attributed to home oxygen use	·		24(89%) were smoking whilst using oxygen, two were lighting pilot lights, one was lighting his wifes cigarette. 4(15%) sustained burns>10% 17(63%) had partial thickness burns. 13(48%) required admission to hospital average LOS 4.4dys).There were 4 (15%) deaths.	none declared

Bibliographic citation	Study type	Evidence level	No patients	Patient characteristic	Intervention	Comparison	Length of f/u	Outcome measures	Effect size	Funding
157 A Hazard of Home Oxygen Therapy. Chang, T. T.; Lipinski, C. A.; Sherman, H. F. J Burn Care Rehabil 2001;22:71-74	case study	3	23	23 patients admitted to burns unit with oxygen related burns. Age 70(50-84). 20 (87%) had COPD.	admission to burns unit	admission to burns unit with oxygen related burns	12yrs	admission to burns unit with oxygen related burn injuries.	16(70%) had burns associated with smoking, 6(26%)cooking, 1(4%) filling LOX. Average burn 3.9% total body surface.13(57%)p ts had inhalation injury, 5(22%) required intubation, 2(8.7%) died. There were 11 incidents recorded in the first 10yrs and 12 recorded in the last 2yrs of study	none declared
158 Brother, have you got a light? Assessing the need for intubation in patients sustaining burn injury secondary to home oxygen therapy Amani H, Lozano D, Blome-Eberwein S. J Burn Care Res 2012;33e280-e285	case study	3	86	Mean age 64(39-90), 56M(65%), 30F(35%). COPD 91%. 75(87%) lighting cigarette, 4((5%) lighting stove. 2(2%)candle, 1(1%)open flame, 4(5%) electrical spark.	to confirm correct decision to	treatment characteristics of patients with flash burns while on HOT(home oxygen therapy)	11yrs	decision to intubate	32 non- intubated %TBSA1.5(0.25- 9), LOS1(1-20), ICU stay 6(1-35). Intubated %TBSA 2(0-15), LOS 7.5(1-41)<.0001. Ventilated 4.5(1- 29), ICU stay 6(1- 35). <.0001	non declared